WO2023080159A1 - リガンド結合核酸複合体 - Google Patents
リガンド結合核酸複合体 Download PDFInfo
- Publication number
- WO2023080159A1 WO2023080159A1 PCT/JP2022/040996 JP2022040996W WO2023080159A1 WO 2023080159 A1 WO2023080159 A1 WO 2023080159A1 JP 2022040996 W JP2022040996 W JP 2022040996W WO 2023080159 A1 WO2023080159 A1 WO 2023080159A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- ligand
- acid complex
- strand
- nucleotides
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 289
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 285
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 285
- 239000003446 ligand Substances 0.000 title claims abstract description 205
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 165
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 141
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 105
- 239000002773 nucleotide Substances 0.000 claims abstract description 78
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 claims abstract description 77
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 claims abstract description 77
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 76
- 230000014509 gene expression Effects 0.000 claims abstract description 73
- 230000000295 complement effect Effects 0.000 claims abstract description 67
- 210000000056 organ Anatomy 0.000 claims abstract description 40
- 238000013519 translation Methods 0.000 claims abstract description 29
- 102100032256 Parathyroid hormone/parathyroid hormone-related peptide receptor Human genes 0.000 claims abstract description 26
- 101710180613 Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 claims abstract description 25
- 102100036829 Probable peptidyl-tRNA hydrolase Human genes 0.000 claims abstract 10
- 230000027455 binding Effects 0.000 claims description 107
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 86
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 70
- -1 morpholino nucleic acid Chemical class 0.000 claims description 32
- 238000013518 transcription Methods 0.000 claims description 27
- 230000035897 transcription Effects 0.000 claims description 27
- 108020004459 Small interfering RNA Proteins 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 230000009368 gene silencing by RNA Effects 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 108091023040 Transcription factor Proteins 0.000 claims description 12
- 102000040945 Transcription factor Human genes 0.000 claims description 12
- 238000001990 intravenous administration Methods 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 108091023037 Aptamer Proteins 0.000 claims description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 3
- 108091030071 RNAI Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 54
- 210000003734 kidney Anatomy 0.000 abstract description 21
- 210000001519 tissue Anatomy 0.000 abstract description 15
- 201000010099 disease Diseases 0.000 abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 210000000988 bone and bone Anatomy 0.000 abstract description 4
- 210000004003 subcutaneous fat Anatomy 0.000 abstract description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract description 2
- 108700026220 vif Genes Proteins 0.000 abstract 2
- 125000005647 linker group Chemical group 0.000 description 74
- 102100036893 Parathyroid hormone Human genes 0.000 description 57
- 239000002585 base Substances 0.000 description 56
- 102000004196 processed proteins & peptides Human genes 0.000 description 42
- 108020004414 DNA Proteins 0.000 description 39
- 239000000047 product Substances 0.000 description 37
- 108020004999 messenger RNA Proteins 0.000 description 32
- 238000000034 method Methods 0.000 description 32
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 31
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 26
- 230000004048 modification Effects 0.000 description 26
- 238000012986 modification Methods 0.000 description 26
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 25
- 108091027963 non-coding RNA Proteins 0.000 description 24
- 102000042567 non-coding RNA Human genes 0.000 description 24
- 125000000539 amino acid group Chemical group 0.000 description 21
- 238000012230 antisense oligonucleotides Methods 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 20
- 239000004055 small Interfering RNA Substances 0.000 description 20
- 108091007767 MALAT1 Proteins 0.000 description 19
- 235000000346 sugar Nutrition 0.000 description 19
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 18
- 125000003277 amino group Chemical group 0.000 description 18
- 239000000074 antisense oligonucleotide Substances 0.000 description 18
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 15
- 230000001419 dependent effect Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 230000009149 molecular binding Effects 0.000 description 15
- 108700011259 MicroRNAs Proteins 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000002679 microRNA Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 239000002777 nucleoside Substances 0.000 description 13
- 230000008685 targeting Effects 0.000 description 13
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 12
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 12
- 102000003982 Parathyroid hormone Human genes 0.000 description 12
- 108090000445 Parathyroid hormone Proteins 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 239000000199 parathyroid hormone Substances 0.000 description 12
- 102000006382 Ribonucleases Human genes 0.000 description 11
- 108010083644 Ribonucleases Proteins 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 102000058004 human PTH Human genes 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 229960001319 parathyroid hormone Drugs 0.000 description 10
- 230000036961 partial effect Effects 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 238000007069 methylation reaction Methods 0.000 description 9
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 9
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 8
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 8
- 101001135738 Homo sapiens Parathyroid hormone-related protein Proteins 0.000 description 8
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 238000005893 bromination reaction Methods 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000000099 in vitro assay Methods 0.000 description 8
- 150000003833 nucleoside derivatives Chemical class 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108010082126 Alanine transaminase Proteins 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 6
- 108091027305 Heteroduplex Proteins 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 6
- 102000043299 Parathyroid hormone-related Human genes 0.000 description 6
- 101710123753 Parathyroid hormone-related protein Proteins 0.000 description 6
- 108091027967 Small hairpin RNA Proteins 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 238000000137 annealing Methods 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 5
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000003682 fluorination reaction Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 201000006938 muscular dystrophy Diseases 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 150000004713 phosphodiesters Chemical class 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 4
- 108010069091 Dystrophin Proteins 0.000 description 4
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 4
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 238000011887 Necropsy Methods 0.000 description 4
- 238000002123 RNA extraction Methods 0.000 description 4
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 4
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 4
- 108091081021 Sense strand Proteins 0.000 description 4
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000003368 amide group Chemical group 0.000 description 4
- 230000001588 bifunctional effect Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000006192 iodination reaction Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000001668 nucleic acid synthesis Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 3
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 101150112014 Gapdh gene Proteins 0.000 description 3
- 108091093094 Glycol nucleic acid Proteins 0.000 description 3
- 108090000031 Hedgehog Proteins Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 108010001831 LDL receptors Proteins 0.000 description 3
- 101100013786 Mus musculus Gapdh gene Proteins 0.000 description 3
- 102100022437 Myotonin-protein kinase Human genes 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 241000209094 Oryza Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- 102000006335 Phosphate-Binding Proteins Human genes 0.000 description 3
- 108010058514 Phosphate-Binding Proteins Proteins 0.000 description 3
- 108091046915 Threose nucleic acid Proteins 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 150000001540 azides Chemical group 0.000 description 3
- 101150006308 botA gene Proteins 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 238000002073 fluorescence micrograph Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 238000010841 mRNA extraction Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000001293 nucleolytic effect Effects 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 210000005239 tubule Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- ZOWOHMFPXMYFKJ-WBTWNKCNSA-N (4S)-4-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]acetyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]propanoyl]amino]-5-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(1S)-1-carboxyethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](C)N)C(C)C)[C@@H](C)CC)C1=CN=CN1 ZOWOHMFPXMYFKJ-WBTWNKCNSA-N 0.000 description 2
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 2
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 101710095342 Apolipoprotein B Proteins 0.000 description 2
- 108010008150 Apolipoprotein B-100 Proteins 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 206010015719 Exsanguination Diseases 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 102000003693 Hedgehog Proteins Human genes 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 description 2
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 2
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- WXJXBKBJAKPJRN-UHFFFAOYSA-N Methanephosphonothioic acid Chemical compound CP(O)(O)=S WXJXBKBJAKPJRN-UHFFFAOYSA-N 0.000 description 2
- 206010068871 Myotonic dystrophy Diseases 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 125000005159 cyanoalkoxy group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 125000001033 ether group Chemical group 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 108010054971 parathyroid hormone-related protein (1-34) Proteins 0.000 description 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 125000002640 tocopherol group Chemical class 0.000 description 2
- 235000019149 tocopherols Nutrition 0.000 description 2
- 229930003802 tocotrienol Natural products 0.000 description 2
- 239000011731 tocotrienol Substances 0.000 description 2
- 229940068778 tocotrienols Drugs 0.000 description 2
- 235000019148 tocotrienols Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- QRZUPJILJVGUFF-UHFFFAOYSA-N 2,8-dibenzylcyclooctan-1-one Chemical group C1CCCCC(CC=2C=CC=CC=2)C(=O)C1CC1=CC=CC=C1 QRZUPJILJVGUFF-UHFFFAOYSA-N 0.000 description 1
- GIXBCECBLAEYKA-UHFFFAOYSA-N 2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]acetic acid Chemical compound OC(=O)COCCOCCOCCN=[N+]=[N-] GIXBCECBLAEYKA-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical compound SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 1
- ORQXBVXKBGUSBA-UHFFFAOYSA-N 2-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)C(N)CC1CCCCC1 ORQXBVXKBGUSBA-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024985 Alport syndrome Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 102000006991 Apolipoprotein B-100 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 1
- VYLJAYXZTOTZRR-BTPDVQIOSA-N CC(C)(O)[C@H]1CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2CC[C@@H]2[C@@]3(C)CCCC(C)(C)[C@@H]3[C@@H](O)[C@H](O)[C@@]12C Chemical compound CC(C)(O)[C@H]1CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2CC[C@@H]2[C@@]3(C)CCCC(C)(C)[C@@H]3[C@@H](O)[C@H](O)[C@@]12C VYLJAYXZTOTZRR-BTPDVQIOSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102100033780 Collagen alpha-3(IV) chain Human genes 0.000 description 1
- 102100033779 Collagen alpha-4(IV) chain Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 101100385232 Escherichia coli (strain K12) creD gene Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000060234 Gmelina philippensis Species 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000710873 Homo sapiens Collagen alpha-3(IV) chain Proteins 0.000 description 1
- 101000710870 Homo sapiens Collagen alpha-4(IV) chain Proteins 0.000 description 1
- 101000710886 Homo sapiens Collagen alpha-5(IV) chain Proteins 0.000 description 1
- 101000589873 Homo sapiens Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102100039880 Interleukin-1 receptor accessory protein Human genes 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000015592 Involuntary movements Diseases 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101000978728 Mus musculus Nephrin Proteins 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 102000018658 Myotonin-Protein Kinase Human genes 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 102100023195 Nephrin Human genes 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
- 108091006597 SLC15A4 Proteins 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100021484 Solute carrier family 15 member 4 Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010049264 Teriparatide Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 208000021022 X-linked recessive inheritance Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 208000021018 autosomal dominant inheritance Diseases 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- TZRFSLHOCZEXCC-HIVFKXHNSA-N chembl2219536 Chemical compound N1([C@H]2C[C@@H]([C@H](O2)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C(C)=C2)=O)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(NC(=O)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP(O)(=O)OC[C@H]2O[C@H](C[C@@H]2SP(O)(=O)OC[C@H]2O[C@H](C[C@@H]2SP(O)(=O)OC[C@H]2O[C@H](C[C@@H]2SP(O)(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)SP(O)(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP(O)(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C3=NC=NC(N)=C3N=C2)OCCOC)SP(O)(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP(O)(=O)OC[C@H]2[C@H](O)[C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)C=C(C)C(N)=NC1=O TZRFSLHOCZEXCC-HIVFKXHNSA-N 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 201000006815 congenital muscular dystrophy Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- XCEBOJWFQSQZKR-UHFFFAOYSA-N dbco-nhs Chemical compound C1C2=CC=CC=C2C#CC2=CC=CC=C2N1C(=O)CCC(=O)ON1C(=O)CCC1=O XCEBOJWFQSQZKR-UHFFFAOYSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 201000009338 distal myopathy Diseases 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000009454 functional inhibition Effects 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000003215 hereditary nephritis Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- VYLJAYXZTOTZRR-UHFFFAOYSA-N hopane-6alpha,7beta,22-triol Natural products C12CCC3C4(C)CCCC(C)(C)C4C(O)C(O)C3(C)C1(C)CCC1C2(C)CCC1C(C)(O)C VYLJAYXZTOTZRR-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 101150010866 ihh gene Proteins 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 108091060283 mipomersen Proteins 0.000 description 1
- 229960004778 mipomersen Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 108010027531 nephrin Proteins 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000002972 pentoses Chemical group 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000022204 primary glomerular disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000010236 regulation of RNA splicing Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
Definitions
- the present invention relates to a nucleic acid complex that regulates the expression or editing of a target gene, its transcription product or its translation product, and more specifically, a ligand-binding nucleic acid in which a ligand that can be delivered to a target organ, cell, or the like is bound to the nucleic acid complex.
- a ligand-binding nucleic acid in which a ligand that can be delivered to a target organ, cell, or the like is bound to the nucleic acid complex.
- nucleic acid drugs are being developed as next-generation drugs because they act on the sequences of transcription products of disease-causing genes to regulate the expression of transcripts and proteins.
- Nucleic acids used as nucleic acid medicines include small interfering nucleic acids (siNA), small interfering RNA (siRNA), double-stranded RNA (dsRNA), microRNA (miRNA), and RNA interference against target nucleic acid sequences.
- siNA small interfering nucleic acids
- siRNA small interfering RNA
- dsRNA double-stranded RNA
- miRNA microRNA
- short hairpin RNA short hairpin RNA (shRNA) molecules that can mediate (RNAi), single stranded Antisense Oligonucleotide (ASO) and antisense double-stranded DNA oligonucleotides using antisense technology, ADO), a hetero-duplex oligonucleotide (HDO) consisting of an antisense strand of DNA and a complementary strand of RNA, a single-stranded heteroduplex oligonucleotide (ss-HDO), etc.
- RNAi short hairpin RNA
- ASO Antisense Oligonucleotide
- ADO antisense double-stranded DNA oligonucleotides using antisense technology
- HDO hetero-duplex oligonucleotide
- ss-HDO single-stranded heteroduplex oligonucleotide
- HDO consists of an antisense strand having a nucleic acid sequence capable of hybridizing to a target gene or target transcript, and a complementary strand (also referred to as a sense strand), which is a nucleic acid strand complementary to the antisense strand.
- a complementary strand also referred to as a sense strand
- a structure in which is annealed to a complementary strand is called a hetero-duplex oligonucleotide (HDO) (Patent Document 1).
- ss-HDO is a single-stranded oligonucleotide as manufactured, comprising an antisense strand consisting of DNA nucleotides or DNA nucleotide analogues, a linker portion consisting of 3-10 nucleotides, and a complementary portion to said antisense strand.
- a structure comprising a sense strand consisting of RNA nucleotides or RNA nucleotide analogues.
- This single-stranded oligonucleotide is an oligonucleotide having the structure XLY (Patent Document 2).
- X is the antisense strand
- Y is the complementary strand to the antisense strand
- L consists of nucleotides that act as a linker.
- this single-stranded oligonucleotide is used as a pharmaceutical composition, it is used in physiological saline, aqueous injections, non-aqueous injections, suspension injections, solid injections, etc., or in blood or plasma.
- the strand and the strand complementary to the antisense strand are annealed as a single molecule with the linker as a fulcrum to form a double-stranded structure.
- such a nucleic acid complex acts as a pharmaceutical composition, it undergoes single-molecule annealing to form a double-stranded structure, so this single-stranded oligonucleotide is one of HDOs.
- a known technique for delivering a nucleic acid complex to a target organ is to add a ligand or the like that can be delivered to the target organ to the nucleic acid complex.
- Ligands and the like include molecules selected from lipids, peptides and proteins. Lipids may be selected from cholesterol, fatty acids, fat-soluble vitamins, glycolipids and glycerides.
- ligands for receptors exposed on the surface of target cells can also be selected as ligands (Patent Document 1).
- cholesterol when used as a ligand, etc., it is taken up into cells via LDL receptors on the cell surface, so it can be delivered particularly to the liver as an organ containing cells with LDL receptors.
- LDL receptors since many cells with LDL receptors also exist in organs other than the liver, when targeting organs other than the liver, they are also delivered to other organs. Consideration is required.
- a ligand-bound nucleic acid complex used as a nucleic acid drug is required to be delivered to an organ and to be taken up by the tissue or cells in the organ to exert an antisense effect.
- the hurdle is high because it is difficult to predict whether the ligand-bound nucleic acid complex will be taken up into cells when a nucleic acid molecule having a molecular weight larger than that of the ligand is bound.
- bioventures and pharmaceutical companies are continuously researching and developing ligands that can be more specifically delivered to target organs.
- PTH receptors are widely distributed throughout the body, but are often expressed in the kidney and bone, and types 1 to 3 have been identified to date.
- the PTH1 receptor is a G protein-coupled receptor.
- Parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP) are known as in vivo ligands for the PTH1 receptor.
- PTH is a hormone secreted from the parathyroid gland and is a peptide hormone consisting of 84 amino acids. It is involved in the action of regulating the blood calcium level, and most of it is mediated by the PTH1 receptor in the kidney. done in the system.
- PTHrP is a 139-173 amino acid protein with N-terminal homology with PTH, but the N-terminus of PTHrP has high homology with PTH, and both bind to a common PTH receptor and exert their actions. .
- PTHrP is secreted from various cells in all organs depending on the time, and physiologically acts mainly in a paracrine/autocrine manner.
- the biological activity of PTH can be reproduced by an N-terminal fragment of amino acid sequence 1-34, ie hPTH(1-34) (US Pat. PTH(1-34) and PTHrP(1-34) are known to have two amphopic alpha-helical domains.
- Biological activities of PTH(1-34) and PTHrP(1-34) include promoting the differentiation of osteoblast progenitor cells and preosteoblasts, suppressing apoptosis of osteoblasts, and promoting osteoblasts. It is known to increase the number of cells and promote osteogenesis.
- PTH1 ligand for the PTH1 receptor
- PTH1 ligand a ligand for the PTH1 receptor
- the PTH1 receptor is one of the G protein-coupled receptors (GPCR, G-protein-coupled receptor) and has seven transmembrane helices. PTH1 receptors are widely distributed throughout the body, and tend to be highly expressed in organs and tissues such as kidney, bone and subcutaneous fat, and in cells such as vascular endothelial cells. Among organs of humans and mice, it is highly expressed especially in the kidney.
- GPCR G protein-coupled receptor
- the problem to be solved by the present invention is to deliver a ligand-binding nucleic acid complex via the PTH1 receptor to an organ of a subject in which the PTH1 receptor is expressed, to obtain a target gene, its transcription product or its translation product. is to modulate the expression or editing of In addition, it can be delivered to the organ of the subject expressing the PTH1 receptor via the PTH1 receptor by intravenous administration or subcutaneous administration, which is an administration method that places less physical burden on the subject, and is targeted. It is to find and perfect a ligand-binding nucleic acid complex capable of regulating the expression or editing of a gene, its transcription product or its translation product.
- the inventors have found that a nucleic acid complex to which a ligand for the PTH1 receptor expressed in each tissue of the kidney and bone of a subject such as a human or mouse is added is delivered to an organ expressing the PTH1 receptor, The invention was completed by confirming that the expression or editing of the target gene, its transcription product or its translation product is regulated.
- the inventors have conducted research on ligands for the PTH1 receptor, and as a result, the PTH1 ligand-binding nucleic acid complex of the present invention is delivered to the target organ and regulates the expression or editing of the target gene, its transcription product or its translation product. I found out.
- the ligand-binding nucleic acid complex of the present invention can be used to treat diseases of organs containing cells expressing PTH1 receptor.
- a ligand-binding nucleic acid complex in which a nucleic acid molecule that regulates the expression or editing of a target gene, its transcription product or its translation product, and a PTH1 ligand are bound via a linker or not.
- A5 is Leu, His, Nle, Ile, Cha, ⁇ -Nal, Trp, Pal, Acc, Phe pX-Phe or absent, where X is OH, halogen, or CH3;
- A6 is Gln;
- A7 is Leu, Nle, Ile, Cha, ⁇ -Nal, Trp, Pal, Acc, Phep-X-Phe or absent, where X is OH, halogen, or CH3;
- A8 is Met, Nva, Leu, Val, Ile, Cha, Acc, Nle or missing;
- A9 is His or missing;
- A10 is Asp or Asn;
- A11 is Leu, Lys, Nle, Ile, Cha, ⁇ -Nal, Trp, Pal, Acc, Phe or p
- a nucleic acid molecule comprising an antisense strand consisting of an oligonucleotide having a nucleobase sequence complementary to a target gene or its transcription product, a nucleobase sequence that specifically binds to a target protein and a decoy consisting of an oligonucleotide having a nucleic acid sequence that is complementary to a target transcription factor.
- nucleic acid strand of the nucleic acid molecule comprises nucleotides, modified nucleotides and/or nucleotide analogues.
- the antisense strand is a gapmer, a gap region containing nucleotides and/or modified nucleotides, and one or more nucleotide analogues and/or
- the ligand-binding nucleic acid complex of [15] comprising wing regions comprising modified nucleotides.
- the complementary strand comprises a center region containing nucleotides and/or modified nucleotides, and wing regions containing one or more nucleotide analogues and/or modified nucleotides arranged at the 5′ end and/or 3′ end of the center region.
- the nucleotide analogue is the group consisting of PNA, GNA, TNA, cEt, tcDNA, morpholino nucleic acids and BNA, guanidine bridged nucleic acid (GuNA) and 2′-O,4′-C-Spirocyclopropylene bridged nucleic acid (scpBNA)
- the ligand-binding nucleic acid complex of [13] which is independently selected from [23]
- the ligand-binding nucleic acid complex of [13] wherein at least one nucleotide or modified nucleotide in the nucleic acid molecule is phosphorothioated or boranophosphated.
- a ligand binding comprising an antisense strand for reducing the expression level of a target transcript in an organ of a subject expressing the PTH1 receptor, and a PTH1 ligand for delivering the antisense strand to the organ of the subject
- a ligand-binding nucleic acid complex wherein the antisense strand comprises a base sequence capable of hybridizing to at least a portion of a target transcript and has an antisense effect on the target transcript Complex.
- the nucleic acid complex is a double-stranded nucleic acid agent consisting of a first nucleic acid strand and a second nucleic acid strand, and the first nucleic acid strand is a base capable of hybridizing to at least part of a target transcript.
- the second nucleic acid strand comprising a base sequence complementary to said first nucleic acid strand and bound to a PTH1 ligand;
- the ligand-binding nucleic acid complex of [24] wherein said first nucleic acid strand is annealed to said second nucleic acid strand.
- the ligand-binding nucleic acid complex of [25] which is a ligand-binding nucleic acid complex for intravenous administration.
- the ligand-binding nucleic acid complex of the present invention can be used to treat diseases of organs containing cells expressing PTH1 receptors.
- the ligand-bound nucleic acid complex of the present invention can be delivered organ- or cell-specifically by the PTH1 ligand, and can regulate the expression or editing of the target gene or its transcription product or its translation product by the nucleic acid molecule.
- Nucleic acid complexes that target disease-causing genes, their transcription products, or their translation products can be used as therapeutic agents for diseases of specific organs.
- the PTH1 ligand-binding nucleic acid complex can be used as a therapeutic drug for renal diseases because it is easily delivered to the kidney where the PTH1 receptor is most expressed among the organs.
- FIG. 1 shows changes in body weight of animals before and after administration of L001-HDO6.
- FIG. 2A shows changes in blood ALT activity three days after administration of L001-HDO6 to mice.
- FIG. 2B shows changes in blood AST activity 3 days after administration of L001-HDO6 to mice.
- FIG. 3 shows changes in mMalat1 ncRNA expression levels in the liver of mice after administration of L001-HDO6.
- FIG. 4 shows changes in mMalat1 ncRNA expression levels in mouse kidneys after administration of L001-HDO6.
- FIG. 5 is a schematic diagram of fluorescence-labeled ASO and HDO used in the kidney distribution test.
- FIG. 6 shows immunostaining images of kidneys 10 minutes, 6 hours, 24 hours and 72 hours after a single intravenous administration of L001-HDO6-Alexa488 to mice.
- FIG. 7 shows changes in mMalat1 ncRNA expression levels in mouse kidneys after intravenous administration of HDO, L001-HDO6, L003-HDO6, L005-HDO6 and L010-HDO6.
- FIG. 8 shows changes in mMalat1 ncRNA expression levels in mouse kidneys after subcutaneous administration of L031-HDO6 and L021-HDO6.
- FIG. 7 shows changes in mMalat1 ncRNA expression levels in mouse kidneys after intravenous administration of HDO, L001-HDO6, L003-HDO6, L005-HDO6 and L010-HDO6.
- FIG. 8 shows changes in mMalat1 ncRNA expression levels in mouse kidneys after subcutaneous administration of L031-HDO6 and L021-
- FIG. 9 shows changes in mMalat1 ncRNA expression level by L021-HDO6, L003-HDO6, L005-HDO6 and L010-HDO6 by in vitro assay using mPth1R stable expression cell lines.
- FIG. 10 shows changes in mMalat1 ncRNA expression level by L021-HDO6 and L011-HDO6 by in vitro assay using mPth1R stably expressing cell lines.
- FIG. 11 shows changes in mMalat1 ncRNA expression level by L031-HDO6 and L040-HDO6 by in vitro assay using mPth1R stably expressing cell line.
- FIG. 12 shows changes in mMalat1 ncRNA expression level by L089-HDO6 and L098-HDO6 by in vitro assay using mPth1R stably expressing cell lines.
- FIG. 13 shows changes in mMalat1 ncRNA expression level by L165-HDO6 and L168-HDO6 by in vitro assay using mPth1R stably expressing cell line.
- FIG. 14 shows changes in mMalat1 ncRNA expression levels caused by L001-ASO by in vitro assay using mPth1R stably expressing cell lines.
- FIG. 15 shows changes in Gapdh mRNA expression levels caused by L010-siRNA by in vitro assay using mPth1R stably expressing cell lines.
- the present invention is a ligand-bound nucleic acid complex in which a ligand is bound to a nucleic acid complex, and the ligand and nucleic acid complex are bound indirectly via a linker or directly without a linker.
- nucleic acid complex refers to a nucleic acid molecule that regulates the expression or editing of a target gene, its transcription product or its translation product.
- nucleic acid molecules include nucleic acid molecules having a complementary nucleic acid sequence to a target gene or its transcription product and having antisense activity. More specifically, the nucleic acid molecule is a single stranded antisense strand (ASO), miRNA, anti-miR, RNA interference (RNAi), short interference RNA (siRNA), short hairpin RNA (shRNA ), antisense double-stranded DNA oligonucleotide (ADO), hetero-duplex oligonucleotide (HDO).
- ASO single stranded antisense strand
- miRNA miRNA
- anti-miR RNA interference
- siRNA short interference RNA
- shRNA short hairpin RNA
- ADO antisense double-stranded DNA oligonucleotide
- HDO hetero-duplex oligon
- nucleic acid molecules include aptamers that have high specificity and high binding affinity for target molecules such as proteins.
- nucleic acid molecules include decoys.
- the function of decoys is that transcription factors bind to binding sites of transcription regulatory factors such as specific promoters of genes, and normally the transcription factors activate genes or regulate the on/off of gene functions. , decoy hybridizes to the transcription factor to suppress the original function of the transcription factor.
- nucleic acid molecules include baits, which are nucleic acid molecules that specifically bind to specific target molecules in cells and that modify the function of the target molecules.
- a "target gene” is a gene to which the antisense strand of the nucleic acid complex of the present invention can bind.
- Target genes include, for example, genes derived from organisms into which the nucleic acid complex of the present invention is introduced, such as genes whose expression is increased in various diseases. Examples thereof include Indian hedgehog gene, interferon gene, apolipoprotein B gene, huntingtin gene, dystrophin gene, DMPK (dystrophia myotonica-protein kinase) gene and the like.
- Indian hedgehog is a secretory protein belonging to the hedgehog family. Located downstream of the transcription factor TAZ, it is known to exacerbate NASH fibrosis.
- IL-1 cytokine interleukin-1 gene
- Skipping exon9 which encodes the transmembrane domain of the pre-messenger RNA (mRNA) IL-1RAcP, as a therapeutic strategy has been reported to result in substantial inhibition of IL-1 signaling (Mol Ther. Nucleic Acids.2013 Jan22(1):e66.doi:10.1038/mtna.2012.58.).
- the apolipoprotein B gene, ApoB-100 is known to cause familial hypercholesterolemia, an inherited metabolic disease. In 2013, the nucleic acid drug mipomersen was launched in the United States.
- Huntington's disease is a chronic progressive neurodegenerative disease that takes an autosomal dominant inheritance pattern and is characterized by involuntary movements, mainly chorea movements, mental symptoms, and dementia as the main symptoms. It is known that 4p16.3 on the short arm of chromosome 4 of the Huntington gene is the causative gene of Huntington's disease.
- Duchenne muscular dystrophy is known to occur in boys as a rule, with muscular dystrophy caused by mutations in the dystrophin gene, an X-linked recessive inheritance. Exon skipping, which skips abnormal exons of the dystrophin gene, is an effective treatment.
- the DMPK gene encodes myotonin protein kinase and is known as the causative gene of myotonic dystrophy, which has the highest incidence among adult muscular dystrophies.
- the COL4A3, COL4A4, and COL4A5 genes are genes that encode the ⁇ 3, ⁇ 4, and ⁇ 5 chains of type 4 collagen that constitutes the basement membrane. develop a syndrome.
- Alport syndrome is a syndrome that presents hearing loss and eye complications in addition to renal failure, and is known to often progress to end-stage renal failure.
- Target transcript refers to any RNA that is directly targeted by the nucleic acid complex of the present invention and synthesized by RNA polymerase.
- target gene transcript corresponds to the “target transcript”. Specifically, mRNA transcribed from the target gene (including mature mRNA, pre-mRNA, and mRNA that has not undergone base modification), non-coding RNA such as miRNA (non-coding RNA, ncRNA), long non-coding RNA RNA (lncRNA), including natural antisense RNA.
- target transcripts examples include pre-mRNA that is the transcript of the IL-1RAcP gene, mRNA that is the transcript of the ApoB-100 gene, mRNA that is the transcript of the IHH gene, and pre-mRNA that is the transcript of the dystrophin gene.
- DMPK mRNA which is a transcription product of the DMPK gene
- Mealat1 metastasis associated lung adenocarcinoma transcript 1 (Malat1) non-coding RNA (ncRNA), and the like.
- Malat1 is a long non-coding RNA (lncRNA) that is highly expressed in malignant tumors such as lung cancer, and is known to reside in the nucleus of muscle cells.
- lncRNA long non-coding RNA
- a “target translation product” is a transcription product of mRNA, excluding non-coding RNA, which is used as a template, and the ribosome connects amino acids carried by the messenger RNA (transfer RNA) according to the codon to create a peptide chain.
- transfer RNA messenger RNA
- “translation product of target gene” and “translation product of target transcript” correspond to "target translation product”.
- Aptamer refers to a target translation product, for example, a nucleic acid molecule that specifically binds to a specific target molecule inside, on the cell membrane, or extracellularly, for example, on the cell membrane or extracellularly.
- Aptamers include DNA-type and RNA-type aptamers, and can be produced by a method known in the art, for example, an in vitro selection method using the SELEX (systematic evolution of ligands by exponential enrichment) method.
- the length of the nucleobase of the aptamer is not particularly limited, but is 10 to 70 bases long, preferably 20 to 50 bases long.
- “Decoy” refers to a nucleic acid having a binding site sequence of a transcription factor (for example, NF-kB) or a similar sequence. If it is an activator, it suppresses transcription; if it is a transcription repressor, it promotes transcription).
- a decoy nucleic acid can be easily designed based on the information of the binding sequence of the target transcription factor.
- the base length of the decoy nucleic acid is not particularly limited, but is 8 to 30 base lengths, preferably 10 to 25 base lengths.
- Nucleic acid or “nucleic acid molecule” means a nucleoside or nucleotide if it is a monomer, an oligonucleotide if it is an oligomer, or a polynucleotide if it is a polymer.
- the term “nucleic acid strand” is also used herein to refer to oligonucleotides. Nucleic acid strands may be prepared in whole or in part by chemical synthesis methods such as the use of automated synthesizers, and may be prepared by enzymatic treatment, including but not limited to polymerase, ligase or restriction enzyme reactions. may
- Nucleoside generally refers to a molecule consisting of a combination of a base and a sugar.
- the sugar moiety of a nucleoside is usually, but not limited to, composed of pentofuranosyl sugars, specific examples of which include ribose and deoxyribose.
- the base portion (nucleobase) of a nucleoside is usually a heterocyclic base portion. Non-limiting examples include adenine, cytosine, guanine, thymine, or uracil, as well as other modified nucleobases (modified bases).
- Nucleotide refers to a molecule in which a phosphate group is covalently bonded to the sugar moiety of the nucleoside. Nucleotides containing a pentofuranosyl sugar typically have a phosphate group attached to the hydroxyl group at the 2', 3', or 5' positions of the sugar.
- Oligonucleotide refers to a linear oligomer formed by covalently linking several to several tens of hydroxyl groups and phosphate groups of sugar moieties between adjacent nucleotides.
- polynucleotide refers to a polymer formed by linking several tens or more, preferably several hundreds or more of nucleotides, which are more numerous than oligonucleotides, by covalent bonds.
- phosphate groups are commonly considered to form internucleoside linkages.
- Antisense technology refers to a technology that uses a nucleic acid molecule with an antisense strand to regulate the amount, activity and/or function of a target nucleic acid.
- the principle of antisense technology using an antisense strand is that a nucleic acid molecule bearing an antisense strand hybridizes to a target nucleic acid to modulate the amount, activity and/or function of the target nucleic acid.
- a nucleic acid molecule with an antisense strand will alter the transcription or translation of a target. Such modulation of expression can be achieved, for example, by degradation or occupancy-based inhibition of the target mRNA.
- RNA target function by degradation is ribonuclease (RNase) degradation of target RNA upon hybridization with a nucleic acid molecule bearing a DNA-like antisense strand.
- RNase ribonuclease
- An antisense strand (ASO) composed of DNA that is capable of hybridizing with the target RNA hybridizes to the target RNA to form a double strand, and then is degraded by RNase.
- Inhibition of expression of target RNA, suppression of action of target RNA, and the like are performed by reducing RNA. This antisense effect is called RNase-dependent antisense effect.
- RNAi RNA interference
- RNAi is antisense-mediated gene silencing that utilizes the RNA-induced silencing complex (RISC). Examples of RNAi include siRNA, shRNA, miRNA, and the like. This antisense effect is also called RNAi-dependent antisense effect.
- antisense effect refers to the effect of regulating expression or editing of a target gene or its transcript by hybridizing the antisense strand of a nucleic acid molecule to the target gene or its transcript (RNA sense strand).
- Modulating the expression or editing of a target gene, its transcript or its translation product means the expression of the target gene or the expression level of the target transcript (herein, “the expression level of the target transcript” is often referred to as “ (referred to as “target transcript level”) suppression or reduction, enhancement, translation inhibition, translation product function inhibition, RNA splicing control (e.g. splicing switch, exon inclusion, exon skipping, etc.), transcript degradation, or targeting It means inhibition of binding of gene to protein.
- target transcript level suppression or reduction, enhancement, translation inhibition, translation product function inhibition, RNA splicing control (e.g. splicing switch, exon inclusion, exon skipping, etc.), transcript degradation, or targeting It means inhibition of binding of gene to protein.
- the antisense effect is caused by inhibition of translation or splicing function conversion effects such as exon skipping, which can be caused by covering the transcript by hybridization, and/or recognition of the hybridized portion. It means said repression caused by degradation of said transcript obtained.
- the antisense effect is obtained by incorporating exons that are excluded from mRNA due to genetic abnormalities in the exon inclusion of a target gene or transcript by the action of antisense, contrary to exon skipping. It refers to the resulting enhancement of normal mRNA expression.
- RNA oligonucleotide in post-transcriptional inhibition of a target gene, when an RNA oligonucleotide is introduced into a cell as an ASO, the ASO forms a partial double strand by annealing with mRNA, the transcript of the target gene. This partial double strand serves as a cover to prevent translation by the ribosome, thereby inhibiting the expression of the target protein encoded by the target gene at the translational level (steric blocking).
- oligonucleotides containing DNA as ASO are introduced into cells, partial DNA-RNA heteroduplexes are formed. Recognition of this heteroduplex structure by RNase results in degradation of the mRNA of the target gene and inhibition of expression of the protein encoded by the target gene at the expression level.
- antisense effects can also be produced by targeting introns in pre-mRNAs.
- antisense effects can also be produced by targeting miRNAs.
- functional inhibition of the miRNA can increase the expression of genes whose expression is normally controlled by the miRNA.
- modulating expression of the target transcript may be reduction in target transcript abundance.
- the DNA double strand is cleaved by DNA nuclease (DNase) in the cell, and then the DNA antisense strand hybridizes to the target RNA to form a double strand. is formed, the target RNA is then degraded by RNase. By repeating this cycle, the expression of the target RNA is inhibited, the action of the target RNA is suppressed, and the like.
- DNase DNA nuclease
- RNA splicing such as, suppresses or enhances the expression of target genes.
- HDO when used as a nucleic acid molecule having an antisense strand, after the complementary strand of HDO RNA is cleaved by RNase in the cell, the DNA antisense strand hybridizes to the target RNA to form a double strand. After formation, the target RNA is degraded by RNase. By repeating this cycle, the expression of the target RNA is inhibited, the action of the target RNA is suppressed, and the like.
- the DNA antisense strand hybridizes to the target RNA, and by controlling RNA splicing such as inhibition of transcription or translation of the target RNA and exon skipping, target It suppresses or enhances expression of genes.
- RNAi RNA interference
- RISC RNA-induced silencing complex
- examples of RNAi include siRNA, shRNA, and the like.
- regulation of RNA target function is by occupancy-based mechanisms, such as those mechanisms naturally utilized by microRNAs.
- MicroRNAs are small non-coding RNAs that regulate the expression of protein-coding RNAs. Binding of a nucleic acid molecule with an antisense strand to a microRNA inhibits the binding of the microRNA to its mRNA target, thereby interfering with the function of the microRNA.
- MicroRNA mimetics can enhance native microRNA function. Nucleic acid molecules with specific antisense strands alter the splicing of pre-mRNA. Regardless of the specific mechanism, sequence specificity makes nucleic acid molecules with antisense strands useful as tools for target validation and gene functionalization, as well as for selective expression of genes involved in disease pathogenesis. used as a therapeutic agent to modulate
- the length of the antisense strand is not particularly limited, it is at least 8 bases, for example 8 to 40 bases, preferably 12 to 30 bases, more preferably 12 to 25 bases, or 13 to 20 bases. is. In some cases, the length of the strand chosen will generally depend on the strength of the antisense effect of the nucleic acid strand on the target, and other factors such as cost, synthetic yield, and the like. In the case of a double-stranded nucleic acid, the chain length may be selected from a chain length such that the Tm value of the double strand is preferably 50°C or higher, more preferably 60°C or higher.
- the length of the complementary strand may be the same as that of the antisense strand. In that case, it is at least 8 bases, for example 8 to 40 bases, preferably 12 to 30 bases, more preferably 12 to 25 bases, or 13 to 20 bases. Moreover, it may be longer or shorter than the chain length of the antisense nucleic acid chain by several bases to ten and several bases.
- “Complementary” or “complementarity” means that through hydrogen bonding, so-called Watson-Crick base pairs (natural base pairs) or non-Watson-Crick base pairs (Hoogsteen base pairs, etc.) can be formed. It means relationship. If a sufficient number of nucleobases of the antisense strand are capable of hydrogen bonding with the corresponding nucleobases of the target gene or target transcript, then the antisense strand and target gene or target transcript are complementary to each other, so the desired An antisense effect occurs. Non-complementary nucleobases between the antisense strand and the target gene or target transcript are permissible provided the antisense strand can specifically hybridize to the target nucleic acid.
- the antisense strand can hybridize to one or more segments of the target gene or target transcript, whereby intervening or flanking segments are involved in hybridization events (e.g., loop structures, mismatches or hairpin structures). do not.
- the antisense strand is said to be complementary to the sequence of the target gene or target transcript.
- Complementary means that the antisense strand is complementary to the extent that it can bind to the target gene or target transcript. Above, 98% or more, or 99% or more complementary. They may be 100% complementary. There may be as many as 0-4 mismatches.
- the "nucleic acid complex" of the present invention is a single-stranded oligonucleotide when manufactured, comprising an antisense strand consisting of DNA nucleotides or DNA nucleotide analogues and a linker portion consisting of 3 to 10 nucleotides. and a sense strand consisting of RNA nucleotides or RNA nucleotide analogs that are complementary to the antisense strand.
- a nucleic acid complex with this structure is called a single stranded heteroduplex oligonucleotide (ss-HDO), and is an oligonucleotide consisting of an XLY structure (Patent Document 4).
- X is the antisense strand
- Y is the complementary strand to the antisense strand
- L consists of nucleotides that act as a linker.
- this single-stranded oligonucleotide is used as a pharmaceutical composition, it is used in physiological saline, aqueous injections, non-aqueous injections, suspension injections, solid injections, etc., or in blood or plasma.
- the strand and the strand complementary to the antisense strand are annealed as a single molecule with the linker as a fulcrum to form a double-stranded structure.
- Such a nucleic acid complex is one of the double-stranded nucleic acid complexes, since one molecule is annealed to form a double-stranded structure when acting as a pharmaceutical composition.
- the nucleic acid complex may be referred to as a nucleic acid molecule.
- the antisense strand comprises nucleotides, modified nucleotides and/or nucleotide analogs.
- the antisense strand means that it has DNA nucleotides, RNA nucleotides, and optionally modified nucleotides, nucleotide analogues in the nucleic acid strand.
- the complementary strand comprises nucleotides, modified nucleotides and/or nucleotide analogs.
- a complementary strand means that it has DNA nucleotides and RNA nucleotides, and may optionally further have modified nucleotides and nucleotide analogues in the nucleic acid strand.
- the complementary strand comprises a central region containing nucleotides and/or modified nucleotides, and one or more nucleotide analogues and/or modified nucleotides arranged at the 5′ end and/or the 3′ end thereof. It has a wing area.
- DNA nucleotide means a naturally occurring DNA nucleotide or a DNA nucleotide whose base, sugar or phosphate binding subunits have been modified.
- RNA nucleotide means a naturally occurring RNA nucleotide or an RNA nucleotide whose base, sugar or phosphate binding subunits have been modified.
- a "modified nucleotide” is the addition of one substituent to the base, sugar or phosphate-linked subunit of a nucleotide, or the substitution of one within a subunit, replacing the entire subunit with a different chemical group.
- DNA may be modified nucleotides from the viewpoint that part or all of the region containing nucleotides is highly resistant to DNase and the like.
- Such modifications include, for example, cytosine 5-methylation, 5-fluorination, 5-bromination, 5-iodination, N4-methylation, thymidine 5-demethylation, 5-fluorination, 5- bromination, 5-iodination, N6-methylation of adenine, 8-bromination, N2-methylation of guanine, 8-bromination, phosphorothioation, boranophosphate, methylphosphonate, methylthiophosphonate, chiral- methylphosphonate, phosphorodithioate, phosphoramidate, 2′-O-methylation, 2′-methoxyethyl (MOE), 2′-aminopropyl (AP), and 2′-fluorination Among them, phosphorothioate is preferred from the viewpoint of excellent pharmacokinetics. Furthermore, such modifications may be applied to the same DNA in combination of multiple types. In addition, as described later, RNA nucleotides may be modified in order to achieve similar effects.
- the number and position of modified nucleotides may affect the antisense effect and the like exhibited by the double-stranded nucleic acid disclosed herein. Since these aspects differ depending on the sequence of the target gene, etc., they cannot be generalized, but a person skilled in the art can determine them by referring to the literature regarding the antisense method described below.
- the antisense effect of the double-stranded nucleic acid complex after modification is measured, and if the obtained measured value is not significantly lower than that of the double-stranded nucleic acid complex before modification (for example, If the measured value of the double-stranded nucleic acid complex after modification is 30% or more of the measured value of the double-stranded nucleic acid complex before modification), the modification can be evaluated.
- the antisense effect can be measured, for example, by introducing a test nucleic acid compound into a cell or the like, as shown in the Examples below, and measuring in the cell or the like suppressed by the antisense effect exhibited by the test nucleic acid compound.
- the expression level of the target gene mRNA level, cDNA level, protein level, etc.
- Nucleotide analogue means a non-naturally occurring nucleotide, in which two or more substituents have been added to the base, sugar or phosphate binding subunit of the nucleotide, or two or more substituted, or substituted entirely with a different chemical group. Examples of analogs with more than one substitution include crosslinked nucleic acids.
- a bridging nucleic acid is a nucleotide analogue to which a bridging unit is added based on two substitutions in the sugar ring, typically the 2' and 4' carbons are attached. is mentioned.
- the first nucleic acid strand further comprises a nucleotide analog from the viewpoint of increasing the affinity for the partial sequence of the transcript of the target gene and/or the resistance to nucleolytic enzymes.
- Nucleotide analogs may be nucleotides that have been modified (crosslinked, substituted, etc.) to increase the affinity for the partial sequence of the transcript of the target gene and/or the resistance to nucleolytic enzymes.
- nucleic acids disclosed as being suitable for use in antisense methods are also referred to as "references relating to antisense methods"
- nucleic acids disclosed in said document hexitol nucleic acid (HNA), cyclohexene nucleic acid (CeNA), peptide nucleic acid (PNA), glycol nucleic acid (GNA), threose nucleic acid (TNA), morpholino nucleic acid, tricyclo-DNA (tcDNA).
- 2′-O-methylated nucleic acids (2′-OMe), 2′-O-methoxyethylated nucleic acids (2′-MOE), 2′-O-ethylated nucleic acids (cEt), 2′-O-amino Propylated nucleic acid (2'-AP), 2'-fluorinated nucleic acid, 2'F-arabino nucleic acid (2'-F-ANA), bridged nucleic acid (BNA).
- the BNA may be a ribonucleotide or deoxyribonucleotide in which the 2'- and 4'-carbons are bridged by two or more atoms.
- Examples of cross-linked nucleic acids are known to those of skill in the art.
- the 2′ and 4′ carbons are 4′-(CH 2 )p—O-2′, 4′-(CH 2 )p—S -2′,4′-(CH 2 )p-OCO-2′,4′-(CH 2 )nN(R 3 )-O-(CH 2 )m-2′ (where p, m and n are integers of 1 to 4, 0 to 2 and 1 to 3, respectively;
- R 3 is a hydrogen atom, an alkyl group, an alkenyl group, a cycloalkyl group, an aryl group, Aralkyl groups, acyl groups, sulfonyl groups, and unit substituents (such as fluorescent or chemiluminescent labeled molecules, nucleic acid cleaving functional groups, or intracellular or nuclear localization signal peptides).
- R 1 and R 2 of the substituent at the 3′ carbon: OR 2 and the substituent at the 5′ carbon: OR 1 are typically hydrogen atoms, which may be the same or different, hydroxyl-protecting groups for nucleic acid synthesis, alkyl groups, alkenyl groups, cycloalkyl groups, aryl groups, aralkyl groups, acyl groups, sulfonyl groups, silyl groups, phosphate groups, and protecting groups for nucleic acid synthesis or —P(R 4 )R 5 (wherein R 4 and R 5 may be the same or different, a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, A mercapto group, a mercapto group protected by a protecting group for nucleic acid synthesis, an amino group, an alkoxy group having 1 to 5 carbon atoms, an alkylthio group having 1 to 5 carbon atoms, a cyano
- Such BNAs include, for example, ⁇ -L-methyleneoxy (4'-CH 2 -O- 2′) BNA) or ⁇ -D-methyleneoxy (4′-CH 2 -O-2′) BNA, ethyleneoxy (4′-(CH 2 )2-O-2′) BNA, also called ENA, Also called ⁇ -D-thio(4′-CH 2 -S-2′)BNA, aminooxy(4′-CH 2 -ON(R 3 )-2′)BNA, 2′,4′-BNANC oxyamino(4'- CH2 -N( R3 )-O-2')BNA, 2',4'-BNACOC, 3'amino-2',4'-BNA, 5'-methyl BNA, (4′-CH(CH 3 )-O-2′)BNA, also called cEt-BNA, (4′-CH(CH 2 OCH 3 )-O-2′)BNA, also called cMOE-BNA, Amido BNA (4
- the base site may be modified.
- base site modifications include cytosine 5-methylation, 5-fluorination, 5-bromination, 5-iodination, N4-methylation, thymidine 5-demethylation, 5-fluorination, 5- Bromination, 5-iodination, N6-methylation of adenine, 8-bromination, N2-methylation of guanine, 8-bromination can be mentioned.
- the modified nucleic acids may have modified phosphodiester binding sites.
- Modifications of the phosphodiester binding site include, for example, phosphorothioation, boranophosphate, methylphosphonate, methylthiophosphonate, chiral-methylphosphonate, phosphorodithioate, and phosphoramidate, but Phosphorothioate is used from the viewpoint of excellent pharmacokinetics.
- Phosphorothioate is used from the viewpoint of excellent pharmacokinetics.
- a plurality of such base site modifications and phosphodiester binding site modifications may be combined for the same nucleic acid.
- modified nucleotides and nucleotide analogs are not limited to those exemplified here.
- Numerous modified nucleotides and nucleotide analogs are known in the art, for example, Tachas et al., US Pat. No. 8,299,039, particularly columns 17-22, may also be used as an embodiment of the present application. .
- nucleotide analogue can be selected and utilized as appropriate, in certain embodiments, the nucleotide analogue is LNA.
- the antisense strand comprises a region containing multiple DNA nucleotides (hereinafter also referred to as "DNA gap region") and one or more nucleotides located at the 5'-end and/or 3'-end of the region. It includes wing regions that contain analogues.
- This antisense strand is also called a Gapmer.
- the chain length of the gapmer is at least 8 bases, such as 8-40 bases, preferably 12-30 bases, more preferably 12-25 bases, or 13-20 bases.
- the plurality of DNA nucleotides may be modified nucleotides.
- the plurality of DNA nucleotides may be nucleotide analogs.
- a region containing nucleotide analogues positioned at the 5′ end of the DNA gap region (hereinafter also referred to as “5′ wing region”) and a region containing nucleotide analogues positioned at the 3′ end of the DNA gap region (hereinafter “ 3' wing region”) are independent of each other, and may contain at least one nucleotide analogue listed in the antisense literature. Nucleic acids (DNA or RNA) or modified nucleotides may be included. In addition, the chain lengths of the 5' wing region and 3' wing region are independently usually 1 to 10 bases, 1 to 7 bases, or 2 to 5 bases.
- the antisense strand is composed of multiple DNA nucleotides, modified nucleotides or nucleotide analogs, or combinations thereof, rather than gapmers.
- This antisense strand is also called non-gapmer.
- the chain length of said non-gapmer is at least 8 bases, such as 8-40 bases, preferably 12-30 bases, more preferably 12-25 bases, or 13-20 bases.
- the complementary strand in the double-stranded nucleic acid complex comprises a region containing a plurality of DNA nucleotides or RNA nucleotides and one or more modified nucleotides arranged at the 5'-end and/or 3'-end of the region. and/or gapmers containing wing regions containing nucleotide analogues.
- the complementary strand in the double-stranded nucleic acid complex may be multiple DNA nucleotides and/or modified nucleotides or nucleotide analogues, RNA nucleotides and/or modified nucleotides or nucleotide analogues. Furthermore, the complementary strand in the double-stranded nucleic acid complex has a center region containing nucleotides and/or modified nucleotides, and one or more nucleotide analogues and/or Alternatively, it may have wing regions containing modified nucleotides.
- the nucleic acid molecule that regulates the expression or editing of the target gene, its transcription product or its translation product consists of an oligonucleotide having a nucleic acid base sequence complementary to the above-mentioned target gene or its transcription product. selected from the group consisting of a nucleic acid molecule comprising an antisense strand, an aptamer having a nucleobase sequence that specifically binds to a target protein, and a decoy consisting of an oligonucleotide having a nucleic acid sequence that is complementary to a target transcription factor. and nucleic acid molecules.
- nucleic acid molecules that regulate the expression or editing of target genes, transcription products thereof, or translation products thereof include nucleic acid molecules selected from the group consisting of ADO, ASO, HDO, and RNAi. .
- Ligands By “ligand” is meant a substance that binds to a biomolecule to form a complex and serve a biological purpose. In some cases, the ligand has a delivery function to the target.
- lipids are preferred ligands from the viewpoint of being able to deliver highly specific and efficient nucleic acid complexes to the liver and the like.
- lipids include lipids such as cholesterol and fatty acids (e.g., vitamin E (tocopherols, tocotrienols), vitamin A, vitamin D), fat-soluble vitamins such as vitamin K (e.g., acylcarnitine), acyl CoA, and the like.
- sugars eg, glucose and sucrose
- preferred ligands are receptor ligands, antibodies, and/or them. and peptides or proteins such as fragments of
- a "PTH1 ligand” is a ligand that can bind to a PTH1 receptor.
- Representative examples of ligands that can bind to the PTH1 receptor include human parathyroid hormone (hPTH), human parathyroid hormone-related protein (hPTHrP), and human tuberoinfundibular peptide (hTIP). mentioned.
- the PTH1 ligand is a peptide consisting of the amino acid sequence represented by the formula below.
- [Chemical 2] A 1 -A 2 -A 3 -A 4 -A 5 -A 6 -A 7 -A 8 -A 9 -A 10 -A 11 -A 12 -A 13 -A 14 -A 15 -A 16 -A 17 -A 18 -A 19 -A 20 -A 21 -A 22 -A 23 -A 24 -A 25 -A 26 -A 27 -A 28 -A 29 -A 30 -A 31 -A 32 -A 33 -A 34 [In the formula, the amino acid sequence is written from the N-terminus to the C-terminus.
- A5 is Leu, His, Nle, Ile, Cha, ⁇ -Nal, Trp, Pal, Acc, Phe pX-Phe or absent, where X is OH, halogen, or CH3;
- A6 is Gln;
- A7 is Leu, Nle, Ile, Cha, ⁇ -Nal, Trp, Pal, Acc, Phep-X-Phe or absent, where X is OH, halogen, or CH3;
- A8 is Met, Nva, Leu, Val, Ile, Cha, Acc, Nle or missing;
- A9 is His or missing;
- A10 is Asp or Asn;
- A11 is Leu, Lys, Nle, Ile, Cha, ⁇ -Nal, Trp, Pal, Acc, Phe or p
- Gly or G Glycine Ala or A: Alanine Val or V: Valine Leu or L: Leucine Ile or I: Isoleucine Ser or S: Serine Thr or T: Threonine Cys or C: Cysteine Met or M: Methionine Glu or E: Glutamic acid Asp or D: Aspartic acid Lys or K: Lysine Arg or R: Arginine His or H: Histidine Phe or F: Phenylalanine Tyr or Y: Tyrosine Trp or W: Tryptophan Pro or P: Proline Asn or N: Asparagine Gln or Q : Glutamine Aib : Aminoisobutyric acid Nle : Norleucine ⁇ -Ala: ⁇ -alanine hPTH: Human PTH Boc: t-butoxycarbonyl Fmoc: 9-fluorenylmethoxycarbonyl Nva: norvaline Abu: ⁇ -aminobutyric acid Ahc
- Peptides represented by the above formula include hPTH(1-34), hPTH(1-34) derivatives, e.g. It includes hPTHrP(1-34), hPTHrP(1-34) derivatives, and peptides lacking n amino acid residues from the N-terminus (where n is an integer from 1 to 9).
- the PTH1 ligand lacks n amino acid residues from the N-terminus of hTIP(1-39), hTIP(1-39) derivatives, and peptides thereof (where n is an integer from 1 to 9). includes things.
- the PTH1 ligand is a hPTH(1-34) peptide, hPTHrP(1-34) peptide, hTIP(1-39) selected from the group of peptides of SEQ ID NOs: 1-168 contained in Table 2 below.
- n amino acid residues an integer from 1 to 9 from the N-terminus.
- PTH1 ligands listed in Table 2 are human PTH1 ligands.
- the PTH1 ligand is a peptide selected from the hPTHrP(1-34) peptides of SEQ ID NOS: 1-88 included in Table 1 and partial peptides thereof.
- the PTH1 ligand is a peptide selected from the hPTH(1-34) peptides of SEQ ID NOS: 89-164 contained in Table 1 and partial peptides thereof.
- the PTH1 ligand is a peptide selected from the hTIP(1-39) peptides of SEQ ID NOS: 165-168 contained in Table 1 and partial peptides thereof.
- the PTH1 ligand is at least 75%, 80%, 85%, 90%, 95% or more identical to L001, L011, L021, L031, L041, L051, L072 from hPTHrP(1-34) Or they may be peptides with homologous amino acid sequences.
- the PTH1 ligand has an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95% or more identical or homologous to L089, L099, L109 from hPTH(1-34). It may be a peptide.
- the PTH1 ligand is a peptide having an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95% or more identical or homologous to L165 from hTIP(1-39) good.
- the ligand is bound to the antisense strand and/or complementary strand of the nucleic acid molecule.
- the ligand is attached to the 3' or 5' end of the nucleic acid strand.
- the ligand is attached to a site other than the end of the nucleic acid strand.
- a method for binding a ligand to the 2-position of the pentose of a nucleotide is known, and can be performed, for example, by the method described in International Publication No. WO2018/003739.
- the "PTH1 ligand” may be a salt of the above peptide, and examples of the salt of the above peptide include sodium salt, potassium salt, calcium salt, hydrochloride, sulfate, nitrate, acetate, methanesulfonate, and toluenesulfonate. , citrate, fumarate, maleate, hydrobromide and the like.
- the above peptides can be produced by known methods such as solid-phase synthesis.
- Binding of ligands and nucleic acid molecules Binding methods of ligands and nucleic acids include covalent bonds, non-covalent bonds such as hydrogen bonds, electrostatic interactions, and hydrophobic interactions. They can be combined by action or the like.
- Examples of the ligand-binding group include, but are not limited to, amino groups, hydroxy groups, carboxylic acid groups, thiol groups, disulfide groups, and azide groups possessed by peptides that are PTH1 ligands.
- Nucleic acid binding groups include the 2-carbon of a nucleoside sugar, the 3- or 5-hydroxy group, the 5-phosphate group of a nucleotide, or the base portion of a nucleoside. Groups to which nucleic acid molecules can be attached also include phosphate groups in oligonucleotides. The nucleic acid molecule and ligand are attached with or without a linker.
- the ligand is attached to the nucleic acid molecule via a linker.
- the ligand may be attached to the antisense strand and/or complementary strand of HDO via a linker.
- Linkers can be cleavable or uncleavable linkers.
- “Cleavable linker” means a linking group that is cleaved under physiological conditions, for example, intracellularly or in an animal body (eg, human body).
- cleavable linkers are selectively cleaved by endogenous enzymes such as nucleases.
- Cleavable linkers include amide, ester, phosphodiester or both esters, phosphate, carbamate, and disulfide bonds, as well as natural DNA linkers.
- a “non-cleavable linker” means a linker that is not cleaved under physiological conditions, eg, in cells or in animals (eg, in humans).
- Non-cleavable linkers include, but are not limited to, phosphorothioate linkages, and linkers composed of modified or unmodified deoxyribonucleosides or modified or unmodified ribonucleosides linked by phosphorothioate linkages.
- the linker is a nucleic acid such as DNA or an oligonucleotide
- the chain length is not particularly limited, but is usually 2 to 20 bases long, preferably 3 to 10 bases long.
- linkers used in the present invention include chain structures such as hydrocarbyl chains or oligomers of repeating units such as ethylene glycol, nucleoside or amino acid units.
- the linker comprises one or more groups selected from alkyl, amino, oxo, amido, disulfide, polyethylene glycol, ether, thioether, and hydroxylamino.
- the linker comprises groups selected from alkyl, amino, oxo, amido and ether groups.
- the linker comprises groups selected from alkyl and amido groups.
- the linker comprises groups selected from alkyl and ether groups.
- the linker comprises at least one phosphorus moiety.
- the linker comprises at least one phosphate group.
- the linker includes at least one neutral linking group.
- the linker has a length of 1-1000 ⁇ .
- Certain linkers have a length of 3-500 ⁇ .
- it has a length of 3-200 ⁇ (the length was estimated based on the crystal structure (PDB 6F3J) in which the PTH1R receptor and the PTH analog bind).
- a bifunctional bond can be used to bond the linker to the oligonucleotide.
- bifunctional linkages are linkages using at least two functional groups. Some of the linker's functional groups are selected to bind to specific sites on the oligonucleotide and others are selected to bind to the ligand portion. Examples of functional groups used for bifunctional attachment of linkers include, but are not limited to, electrophiles to react with nucleophiles and nucleophiles to react with electrophiles. be done.
- bifunctional linkages are available with one or more groups selected from amino, hydroxyl, carboxylic acid, thiol, alkyl, alkenyl, and alkynyl.
- linkers include, but are not limited to, 6-aminohexanoic acid (AHA or AHEM) and (2,5-dioxypyrrolidi-1-yl)4-(2-azatricyclo[10.4.0. 04,9]hexadeca-1(16),4,6,8,12,14-hexe-10-nin-2-yl-4-oxobutanoate (DBCO-NHS), 3-mercaptopropionic acid, succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate
- linkers include, but are not limited to, substituted or unsubstituted C 1 -C 10 alkyl, substituted or unsubstituted C 2 - C10 alkenyl or substituted or unsubstituted C2 - C10 alkynyl, a non-limiting list of preferred substituents include hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol
- the linker can be selected from compounds having the following structures in Table 3 and derivatives thereof.
- the n of the polyethylene glycol group in Table 3 is 1-200, preferably 1-100, more preferably 1-50.
- the linker may consist of 2-20 linker-nucleosides. In certain embodiments, such linker-nucleosides are consecutive modified nucleosides. In certain embodiments, such linker-nucleosides may contain modified sugar moieties. In certain embodiments, linker-nucleosides are unmodified. In certain embodiments, the linker-nucleoside optionally comprises a protected heterocyclic base selected from purines, substituted purines, pyrimidines or substituted pyrimidines.
- the linker can be selected from compounds having the following structures and derivatives thereof.
- X is the ligand binding site and Y is the nucleic acid molecule binding site.
- a compound having an active ester of formula 4 below (Where X is a ligand binding site), a compound represented by the following formula: (where Y is a nucleic acid molecule binding site), reacting with an oligonucleotide having a terminal amine, (wherein X is the ligand binding site and Y is the nucleic acid molecule binding site.
- the nucleic acid molecule is an oligonucleotide selected from or using natural nucleotides, modified nucleotides, nucleotide analogues).
- a linker represented by Formula 6 above can be obtained.
- linkers containing phosphate/triethylene glycol can be used.
- a linker represented by the following formula 7 can be used.
- X is a ligand
- a linker represented by the formula of Chemical Formula 9 above can be obtained.
- the linker is a structure represented by Formula 10 below.
- X is a ligand-binding site, Y is a nucleic acid molecule-binding site, W is a phosphodiester or amino group, Z is a pyrrolidinyl group represented by the following formula 11; j is 0 or 1; yes; n is about 1 to about 10; m is about 1 to about 10; l is 0 or 1-4; and l is 1 when X is an amino group
- linker-click chemistry is prepared using linker-click chemistry. Additional linkers suitable for use in some embodiments are described in "Click Chemistry for Biotechnology and Materials Science” Ed. It can be prepared by click chemistry as described in Joerg Laham, Wiley 2009, which is incorporated herein by reference in its entirety.
- a compound represented by the following formula: (wherein Y is a nucleic acid molecule binding site) with an oligonucleotide having a terminal amine, A compound represented by the formula of Formula 14 was obtained. This is reacted with an azide-bearing ligand to (wherein X represents the ligand binding site and Y represents the nucleic acid molecule binding site) A linker represented by the above formula 15 was obtained.
- a maleimide linker can be used as the linker.
- the linker has a structure represented by Formula 16 below.
- X is the ligand binding site and Y is the nucleic acid molecule binding site.
- a compound represented by the following formula: (wherein Y is a nucleic acid molecule binding site) is reacted with an oligonucleotide having a terminal amine, A compound represented by the formula of Chemical Formula 19 was obtained. By reacting this with a ligand conjugate moiety having a maleimide, (In the formula, X is a ligand binding site and Y is a nucleic acid molecule binding site.) A linker represented by the above formula 20 was obtained.
- a compound represented by the following formula: and a compound represented by the following formula: (wherein Y is a nucleic acid molecule binding site) is reacted with an oligonucleotide having a terminal amine, A compound represented by the formula of Chemical Formula 23 above was obtained. By reacting this with a thiol-bearing ligand conjugate moiety, (wherein X is the ligand binding site and Y is the nucleic acid molecule binding site) A linker represented by the above formula 24 was obtained.
- linkers that contain disulfide bonds can be used.
- the linker comprises an activated disulfide that forms a disulfide bond with the ligand binding moiety.
- a compound represented by the following formula: and a compound represented by the following formula: (wherein Y is a nucleic acid molecule binding site) is reacted with an oligonucleotide having a terminal amine, A compound represented by the above formula 27 was obtained. By breaking the disulfide bond, A compound represented by the above formula 28 was obtained. By reacting this with a thiol-bearing ligand conjugate moiety, (wherein X is the ligand binding site and Y is the nucleic acid molecule binding site) A linker represented by the above formula 29 was obtained.
- a linker is chemically attached to the PTH1 ligand. Via the linker, the PTH1 ligand is attached to a functional group for attachment to the oligonucleotide.
- a compound represented by the following formula: (In the formula, Y is a functional group for direct or indirect attachment to oligos, such as azide, maleimide, etc.), (Wherein, X is the ligand binding site and Y is the nucleic acid molecule binding site)
- a linker was obtained by introducing a linker into the ligand-binding portion represented by the formula of Chemical Formula 31 above.
- the disease targeted by the ligand-binding nucleic acid complex of the present invention may be any disease associated with the target organ and the tissues and cells in the organ.
- diseases include diabetes, metabolic syndrome, heart disease, muscular dystrophy, myotonic dystrophy, Becker muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreyfus muscular dystrophy, facioscapulohumeral.
- muscular dystrophy muscular dystrophy, limb-girdle muscular dystrophy, oculopharyngeal muscular dystrophy, chronic kidney disease (CKD), renal fibrosis, diabetic nephropathy, chronic glomerulonephritis, IgA nephropathy, lupus nephritis, primary glomerular disease, chronic obstructive
- COPD lung disease
- emphysema interstitial pneumonia
- pulmonary fibrosis heart disease
- muscle disease and the like.
- a composition containing a ligand-binding nucleic acid complex in some embodiments can be formulated by known pharmaceutical methods. For example, capsules, tablets, pills, liquids, powders, granules, fine granules, film coating agents, pellets, lozenges, sublingual agents, chewing agents, buccal agents, pastes, syrups, suspensions, Enteral (oral, etc.) or It can be used enterally.
- pharmacologically acceptable carriers specifically sterile water, physiological saline, vegetable oils, solvents, bases, emulsifiers, suspending agents, surfactants, pH adjusters , stabilizers, flavoring agents, fragrances, excipients, vehicles, preservatives, binders, diluents, tonicity agents, soothing agents, bulking agents, disintegrants, buffers, coating agents, lubricants, Coloring agents, sweetening agents, thickening agents, flavoring agents, solubilizing agents, other additives, and the like can be appropriately combined.
- the ligand-bound nucleic acid complex in the embodiment of enteral administration should be formulated with a substance that enhances the permeability of the colonic mucosal epithelium (e.g., medium-chain fatty acids, long Complexes (mixed micelles, emulsions) of chain unsaturated fatty acids or their derivatives (salts, esters or ethers)) and surfactants (nonionic surfactants, anionic surfactants) good too.
- a substance that enhances the permeability of the colonic mucosal epithelium e.g., medium-chain fatty acids, long Complexes (mixed micelles, emulsions) of chain unsaturated fatty acids or their derivatives (salts, esters or ethers)
- surfactants nonionic surfactants, anionic surfactants
- Preferred modes of administration of a composition containing a ligand-binding nucleic acid complex in some embodiments are not particularly limited, and are enteral (oral, etc.) or parenteral, more specifically intravenous administration, Intraarterial administration, intraperitoneal administration, subcutaneous administration, intradermal administration, intrathecal administration, intratracheal administration, rectal administration and intramuscular administration, and administration by infusion.
- a composition containing a ligand-binding nucleic acid complex in some embodiments can be used for animals including humans, but non-human animals are not particularly limited, and various livestock, poultry, pets, Experimental animals and the like can be used as subjects.
- the dosage or intake depends on the subject's age, body weight, symptoms, health condition, type of composition (medicine, food and drink etc.), etc., but the effective intake of the composition according to an embodiment is preferably 0.001 mg/kg/day to 50 mg/kg/day in terms of nucleotides.
- Example 1 Synthesis and purification of PTH1 ligand
- the polypeptides listed in Table 1, which are PTH1 ligands of the present invention, are introduced into oligonucleic acids in the synthesis pattern shown in Table 4.
- modification pattern A is, for example, L001-L009, L031-L040, L080-L098, etc. from the C-terminus of polypeptides such as the second amino acid Lysine side chain amino group substituted with PEG3-Azide group (K -PEG3-Azide), with the azide group of K-PEG3-Azide and a 5′-dibenzocyclooctyne-succinyl-hexylamino oligonucleic acid modified with a dibenzocyclooctyne-succinyl-hexylamino group at the 5′ end of the oligonucleotide Modification patterns by binding and attaching polypeptides such as L001-L009, L031-L040, L080-L098 to oligonucleotides.
- polypeptides such as the second amino acid Lysine side chain amino group substituted with PEG3-Azide group (K -
- modification pattern C is, for example, L021-L030, L051-L088, L109-L168, etc.
- the side chain amino group of Lysine at the C-terminus of a polypeptide is substituted with a PEG3-Azide group (K-PEG3-Azide ), and the azide group of K-PEG3-Azide and a 5′-dibenzocyclooctyne-succinyl-hexylamino oligonucleic acid modified with a dibenzocyclooctyne-succinyl-hexylamino group at the 5′ end of the oligonucleotide are combined to form an oligo Modification patterns by binding polypeptides such as L021-L030, L051-L088, L109-L168 to nucleotides.
- the linker structure when L001 and an oligonucleotide are bound is K-PEG3-Unit.
- Unit refers to the linker portion on the oligo side of the linker structure.
- the binding site the structure in which the azide and the DBCO structure react
- the phosphate group located at the 5' end of the oligo side are the Units.
- modification pattern B is, for example, L011-L020, L041-L050, L099-L108, etc. from the C-terminus of the cysteine thiol at the 2nd amino acid and 3 pyridyldithiopropionyl groups at the 5' end modified 5 '-3 Pyridyldithiopropionyl-hexylaminooligonucleotide is a modification pattern by binding with an SS bond and introducing it into an oligonucleotide.
- the linker structure when L099 and an oligonucleotide are bound is CS-Unit).
- Unit refers to the linker portion on the oligo side of the linker structure.
- the binding site (SS bond) and the phosphate group located at the 5' end of the oligo are Units.
- the solid-phase peptide synthesis method developed by Merrifield et al. can be used as a method for synthesizing the ligand linker LG001 for introducing the oligonucleic acid of L001.
- the solid-phase peptide synthesis method developed by Merrifield et al. can be used.
- Commonly available automated peptide synthesizers may be used.
- synthesis of polypeptide L001 can be performed using an automated peptide synthesizer 430A (Applied Biosystems).
- the purified polypeptide is obtained by subjecting the resulting peptide-containing resin to gel filtration.
- PTH1 ligands used in the present invention can be prepared by a person skilled in the art by a similar method.
- the peptides listed in Table 1 can be synthesized according to the following method.
- suitable protecting groups such as Boc, Fmoc, benzyl, t-butyl groups
- a reagent capable of selectively deprotecting the protecting group of the amino group of the main chain portion of the amino acid to the amino acid corresponding to the C-terminus, only the amino group of the main chain portion is selectively removed.
- HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate is added in advance to the deprotected amino group of the main moiety.
- L001 the polypeptide of SEQ ID NO: 1 in Table 1
- Ligand linker LG001 for introducing L001 (polypeptide of SEQ ID NO: 1) described in Table 1 was obtained from Peptide Institute Inc. Purity was approximately 99% by HPLC. The molecular weight by mass spectrometry (ESI-MS) was 4188.8 (which was consistent with the calculated molecular weight of 4188.8). L002-L168 can also be synthesized by a similar method.
- the nucleic acid complex of the present invention may have an antisense strand capable of hybridizing to a target gene or target transcript and exhibits an antisense effect.
- Any possible complementary strand combination can be used. For example, it is possible to select from ASO, HDO, and siRNA consisting of the following sequences, and when targeting different diseases, since the target transcripts are different, an antisense strand having a nucleic acid sequence corresponding to each target can be used.
- nucleic acid complex in which a PTH1 ligand is bound to ASO having an antisense strand and/or HDO and/or siRNA having a strand complementary to the antisense strand consisting of the following nucleic acid sequences in Table 5 can be used. .
- lowercase letters represent DNA
- underlined uppercase type represents LNA (C means LNA methylcytosine)
- uppercase letters represent RNA
- uppercase italic letters represent 2′-O-methyl sugar modifications
- Lowercase italics represent morpholino nucleic acids
- underlined lowercase italics represent 2'-fluoro-sugar modifications
- asterisks represent phosphorothioate linkages.
- Example 2 L001-HDO6 targeting mouse Malat1 (mMalat1) ncRNA was produced using the antisense strand (SEQ ID NO: 179), the complementary strand (SEQ ID NO: 180), and the PTH1 ligand L001.
- Lower case letters represent DNA
- underlined upper case type represents LNA (C stands for LNA methylcytosine)
- upper case letters represent RNA
- double underlined upper case letters represent 2′-O-methyl sugar modifications
- asterisks Marks represent phosphorothioate linkages.
- SEQ ID NO: 179 is an antisense strand consisting of 16 nucleic acids (16mer) targeting mMalat1 ncRNA, targeting mMalat1 ncRNA and composed of a sequence capable of hybridizing to the target site of mouse Malat1 ncRNA.
- SEQ ID NO: 180 is a complementary strand consisting of 16 nucleic acids (16mer) having a sequence complementary to the antisense strand of SEQ ID NO: 179, and is composed of a sequence that can hybridize to the antisense strand of SEQ ID NO: 179. .
- a ligand molecule can be bound to the 5' end of the complementary strand of SEQ ID NO: 180 by performing a conjugation reaction as follows.
- each L002-L010, L021-L040, L051-L098, L0109-L168 ligand-conjugated ASOs, HDOs and siRNAs can be generated.
- the antisense strand of SEQ ID NO: 179 (0.2 mM, 750 ⁇ L) and the complementary strand of SEQ ID NO: 180 (0.20 mM, 750 ⁇ L) bound to L001 were mixed, and L001-HDO6 (0. 1 mM, 1.5 mL).
- L001-HDO6 is added to normal saline (Otsuka Saline Injection (Otsuka Pharmaceutical)), the solution is heated at 95° C. for 5 minutes, and the solution is slowly cooled to room temperature to form an annealed double-stranded complex. A double-stranded complex, L001-HDO6, was thereby generated.
- a PTH1 ligand-binding HDO is prepared by the same method. is possible.
- the Tm of HDO6 introduced with L001, L003, L005, L010, L021, L040, L089, L098, L098, L165 and L168 was as shown in Table 7 below.
- the nucleic acid complex used in this example is L001-HDO6, a 16-mer HDO targeting mouse Malat1 ncRNA generated in Example 2 conjugated with L001 as a ligand.
- the inventors prepared these oligos in physiological saline (Otsuka Pharmaceutical Co., Ltd.) to 100 ⁇ M, and double-stranded HDO was denatured in a block bath (CDB-105, AS ONE) at 90° C. for 5 minutes, followed by natural cooling. Annealing operation was performed by returning to room temperature in (about 2 hours).
- mice Since PTH1 receptor, PTH, and PTHrP have little species difference between humans and mice, c57BL/6J mice (25 mice, Charles River Japan, female, 4 weeks old upon arrival) were used as test subjects. The animals were housed in plastic cages in groups of 5 under an environment of room temperature (24 ⁇ 2°C), humidity (55 ⁇ 5%) and 12-hour lighting (8:00-20:00). (MF, Oriental Yeast Co., Ltd.) and acclimatized for one week.
- room temperature 24 ⁇ 2°C
- humidity 55 ⁇ 5%
- 12-hour lighting 8:00-20:00
- vehicle Saline, Otsuka Pharmaceutical
- L001 complementary chain (1 ⁇ mol/kg) administration group
- the L001 complementary strand (1 ⁇ mol/kg) administration group was used as a negative control.
- hemostasis at the administration site was confirmed, and the animals were returned to their breeding cages. Necropsy was performed 3 days after administration (Day 3).
- mice On the day of necropsy, the mice were weighed, and under anesthesia with isoflurane (3-5% induction, 1-3% maintenance), intracardiac blood collection (Thermosyringe SS-01P2525, containing anticoagulant heparin) was performed, and exsanguination. were euthanized by The abdomen was opened, and the liver and kidney were removed. The excised organs were immediately immersed in ISOGEN and subjected to mRNA extraction.
- the blood sample was placed in a 1.5 ml Eppendorf tube, centrifuged at 10,000 rpm/5 minutes, and the supernatant was frozen (-30°C) and stored for measurement of blood liver deviating enzymes Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST). Using.
- RNA disruption was performed using a biomasher, GentleMACS Dissociators (Miltenyi Biotec) or FastPrep-24 5G (MP Biomedicals).
- Total RNA was extracted from the tissue homogenate using ReliaPrep TM RNA Tissue Miniprep System (Z6112, Promega).
- cDNA was prepared from Total RNA by reverse transcription using PrimeScript TM RT Master Mix (TaKaRa, RR036A). The mRNA expression of each gene was measured with a real-time PCR system Step One Plus (Applied Biosystems).
- TaqMan probe sets for mouse Malat1 Mm 01227912-s1, Thermo Fisher Scientific
- 18S rRNA Mm 03928990-g1, Thermo Fisher Scientific
- Blood ALT/AST activity was measured using a Test Wako ALT/AST measurement kit (Fujifilm Wako Pure Chemical Industries, Ltd., 431-3090) and an enzyme calibrator (Fujifilm Wako Pure Chemical Industries, Ltd., 416-57191). .
- mice were administered through the tail vein at a dose of 10 ml/kg, but no behavioral changes were observed immediately after administration.
- FIG. 2A shows changes in blood ALT activity three days after administration of mMalat1 oligo to mice.
- FIG. 2B shows changes in blood AST activity 3 days after administration of mMalat1 oligo to mice.
- ALT and AST activities of the mMalat1 oligo-administered group showed no significant change compared to the Vehicle-administered group.
- Kidney Renal mMalat1 ncRNA expression was significantly decreased in the L001-HDO6 administration group compared to the vehicle administration group and the L001 complementary chain administration group (Fig. 4).
- L001-HDO6 was administered intravenously to a subject, whereby L001-HDO6 was delivered to an organ in which the PTH1 receptor was expressed, such as the liver, resulting in the expression of the target transcript, mMalat1 ncRNA.
- FIG. 5 shows fluorescence-labeled HDO used for histological examination by immunostaining image.
- Annealing was performed by the method described in Example 2 for the fluorescence-labeled ASO in which Alexa488 was bound to the 5′ end of the antisense strand (SEQ ID NO: 179) prepared in Example 2 and the L001 complementary strand (SEQ ID NO: 180). , produced a fluorescently labeled HDO (L001-HDO6-Alexa488) by forming a double-stranded complex.
- kidney glomeruli were treated with Nephrin (primary antibody Mouse Nephrin Affinity Purified Polyclonal Antibody, Goat IgG (R&D Systems: AF3459)), secondary antibody Alexa Flour 594 chicken anti-goat I gG(H+L) (A-21468, Invitrogen), and cell nuclei containing DNA were stained with DAPI (4′,6-diamidino-2-phenylindole) solution. Fluorescent images of pathological sections were taken with an Olympus VS120 Slide Scanning System.
- Nephrin primary antibody Mouse Nephrin Affinity Purified Polyclonal Antibody, Goat IgG (R&D Systems: AF3459)
- secondary antibody Alexa Flour 594 chicken anti-goat I gG(H+L) A-21468, Invitrogen
- DAPI 4′,6-diamidino-2-phenylindole
- FIG. 6 shows that 1 ⁇ mol/kg of fluorescence-labeled HDO (L001-HDO6-Alexa488) was administered to c57BL/6J mice i.v. v. 10 minutes, 6 hours, 24 hours and 72 hours after administration of a single dose, immunohistochemical staining images of kidneys are shown.
- Each post-dose time photograph consists of four photographs.
- the upper left photograph is an ultraviolet (UV) fluorescence image showing the results of DAPI staining.
- the lower left photograph is a red fluorescence image (red-Alexa594) showing the results of staining with an anti-Nephrin antibody.
- the upper right photograph is a green fluorescence image showing the result of staining with L001-HDO6-Alexa488 (green-Alexa488).
- the lower right photo is a merged image of the above three photos.
- L001-HDO6 by intravenous administration of L001-HDO6 to a subject, L001-HDO6 was delivered to organs expressing PTH1 receptors, such as the liver, and remained in the renal tubules in the liver for 72 hours. The results showed that the
- the nucleic acid complex used in this example is a 16-mer HDO or ASO targeting the mouse Malat1 ncRNA prepared in the example, to which a PTH1 ligand is attached.
- the inventors prepared these oligos in physiological saline (Otsuka Pharmaceutical Factory), oligos for animal evaluation in block bath (CDB-105, AS ONE), and double-stranded HDO for cell evaluation. Denaturation was performed at 95° C. for 10 minutes in a T100 thermal cycler (Bio-Rad), followed by cooling (about 2 hours) and annealing to room temperature. Oligos for animal evaluation were final adjusted to 100 nmol/mL in physiological saline, and oligos for cell evaluation were prepared at various concentrations in DMEM (Invitrogen) with 0.1% FCS.
- DMEM Invitrogen
- mice C57BL/6J mice (Japan SLC, female, 4 weeks old at the time of arrival) were used. The animals were housed in plastic cages in groups of 5 under an environment of room temperature (24 ⁇ 2°C), humidity (55 ⁇ 5%), and 12-hour lighting (7:00-19:00). (MF, Oriental Yeast Co., Ltd.) and acclimatized for one week.
- vehicle Saline, Otsuka Pharmaceutical Factory
- PTH1 ligand-HDO 1 ⁇ mol/kg
- the mice were restrained in a restraint device while awake, and the reagent was slowly administered (10 mL/kg, Day 0) through the tail vein or subcutaneously on the back of the neck. After administration, hemostasis at the administration site was confirmed, and the animals were returned to their breeding cages. Necropsy was performed 3 days after administration (Day 3).
- ReliaPrep TM RNA Tissue Miniprep System (Promega) was used for extraction of total RNA from the tissue homogenate.
- cDNA was prepared from Total RNA by reverse transcription using PrimeScript TM RT Master Mix (TaKaRa).
- the mRNA expression of each gene was measured with a real-time PCR system Step One Plus (Applied Biosystems).
- TaqMan probe sets for mouse Malat1 (Mm 01227912-s1, Applied Biosystems), mouse Gapdh (Mm99999915_g1, Applied Biosystems) mRNA were used.
- L001 is a peptide consisting of 34 amino acid residues
- L003 is a peptide consisting of 32 amino acid residues lacking 2 amino acid residues from the N-terminus of L001
- L005 lacks 4 amino acid residues from the N-terminus of L001. It is a peptide consisting of 30 amino acid residues
- L010 is a peptide consisting of 25 amino acid residues lacking 9 amino acid residues from the N-terminus of L001.
- HDO bound with a peptide consisting of 34 amino acid residues of L001 inhibited the expression of the target gene. Furthermore, HDO bound to peptides consisting of 32, 30, and 25 amino acid residues in which 2, 4, and 9 amino acid residues were deleted from the N-terminal side of the peptide consisting of 34 amino acid residues, respectively, also inhibited the expression of target genes. The results showed that peptides lacking at least 9 amino acid residues from the N-terminal side of the peptide had an antisense effect.
- L031 is a peptide consisting of 35 amino acid residues
- L021 is a peptide consisting of 34 amino acid residues. The difference in the amino acid sequences of these peptides was the presence or absence of T on the C-terminal side or the difference in the position of K (Lys), but both peptides significantly inhibited the expression of the target gene.
- mPth1R mouse Pth1R
- the clone cell line stably expressing mPth1R used to evaluate the action of the PTH1 ligand is a cell line that has a cAMP-inducing ability with an IC50 of approximately 100 pM at 33K agonist activity.
- mPth1R stably expressing cell line was seeded in a 96-well plate at 1.5 ⁇ 10 4 cells/well. Twenty-four hours after seeding, the medium in each well was removed by aspiration, and 100 ⁇ L of PTH1 ligand-HDO prepared in DMEM containing 0.1% FBS at various concentrations was added to each well. Total RNA was extracted from the cells according to the protocol of RNA purification kit of SV 96 Total RNA Isolation System (Promega). That is, 24 hours after the addition of PTH1 ligand-HDO, the medium in each well was removed by aspiration, and then each well was washed with PBS.
- RNA Lysis Buffer attached to the RNA Purification Kit was added to each well to lyse the cells.
- total RNA was obtained according to the SV 96 Total RNA Isolation System (Promega).
- PrimeScript TM RT Master Mix (TaKaRa) was used for reverse transcription from Total RNA to cDNA.
- the mRNA expression of each gene was measured using the real-time PCR system Step One Plus (Applied Biosystems). Malat1 (Mm 01227912-s1, Applied Biosystems) was used for target gene analysis, and a TaqMan probe of Gapdh (Mm99999915_g1, Applied Biosystems) was used as an internal standard gene.
- L001-ASO L001-ASO which is an ASO bound to the PTH1 ligand L001, decreased Malat1 ncRNA expression in a concentration-dependent manner, with an IC50 of 1.25 nM (FIG. 14).
- the results showed that ASO bound to the PTH1 ligand consisting of the peptide of SEQ ID NO: 1 had a concentration-dependent antisense effect on the target gene.
- the PTH1 ligands of the present invention bound to single-stranded nucleic acid molecules and exhibited concentration-dependent antisense effects on target genes.
- the nucleic acid complex of the present invention may have an antisense strand capable of hybridizing to a target gene or target transcript and exhibits an antisense effect.
- Any possible complementary strand combination can be used.
- siRNA consisting of the following sequences, and when targeting different diseases, since the target transcripts are different, a nucleic acid molecule having an antisense strand with a nucleic acid sequence corresponding to each target can be used.
- the nucleic acid complex can use siRNA consisting of the following antisense strand (SEQ ID NO: 181) and guide strand (SEQ ID NO: 182).
- uppercase italics represent 2'-O-methyl sugar modifications
- underlined lowercase italics represent 2'-fluoro-sugar modifications
- asterisks represent phosphorothioate linkages.
- SEQ ID NO: 181 is an antisense strand consisting of 23 nucleic acids (23mer) targeting mGapdh mRNA, which is composed of a sequence capable of hybridizing to the target site of mouse Gapdh mRNA.
- SEQ ID NO: 182 is a complementary strand consisting of 23 nucleic acids (21mer) having a sequence complementary to the antisense strand of SEQ ID NO: 181, and is composed of a sequence that can hybridize to the antisense strand of SEQ ID NO: 181. .
- a ligand molecule can be bound to the 5' end of the complementary strand of SEQ ID NO: 182 by performing a conjugation reaction in the same manner as HDO.
- the PTH1 ligand-binding nucleic acid complex used in this example is L010-siRNA obtained by binding the PTH1 ligand L010 according to the method of Example 2 to the 23-mer siRNA targeting mouse Gapdh mRNA described above.
- the inventors prepared these oligos in physiological saline (Otsuka Pharmaceutical Co., Ltd.), and denatured the siRNAs for cell evaluation in a T100 thermal cycler (Bio-Rad) at 95°C for 10 minutes, followed by cooling ( about 2 hours), and an annealing operation was performed to return to room temperature. Oligos for animal evaluation were finally adjusted to 100 nmol/mL in physiological saline, and oligos for cell evaluation were prepared at various concentrations using Opti-MEM (Invitrogen).
- a cell line was used in which mouse Pth1R (mPth1R) was stably expressed in the NIH/3T3 cell line by the PiggyBac transposon method.
- mPth1R stably expressing cell line was seeded in a 96-well plate at 3.75 ⁇ 10 3 cells/well. Four hours after seeding, the medium in each well was removed by aspiration, and 100 ⁇ L of L010-siRNA of various concentrations prepared in Opti-MEM was added to each well. Total RNA was extracted from the cells according to the protocol of RNA purification kit of SV96 Total RNA Isolation System (Promega). That is, 72 hours after addition of L010-siRNA, the medium in each well was removed by aspiration, and then each well was washed with PBS.
- RNA Lysis Buffer attached to the RNA Purification Kit was added to each well to lyse the cells.
- total RNA was obtained according to the SV96 Total RNA Isolation System.
- PrimeScript RT Mster Mix (TaKaRa) was used for reverse transcription from Total RNA to cDNA.
- Fig. 15 shows the test results. 10 ⁇ M of siRNA bound to PTH1 ligand L010 reduced mGapdh mRNA expression by 14% compared to the control (0 ⁇ M) administration group.
- the PTH1 ligand of the present invention exhibited an antisense effect against the target gene even when bound to siRNA.
- the ligand-binding nucleic acid complex of the present invention can be used for nucleic acid drugs that are delivered to organs having PTH1 receptors and regulate the expression or editing of target genes or their transcripts.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
[1] 標的遺伝子、その転写産物又はその翻訳産物の発現又は編集を調節する核酸分子と、PTH1リガンドが、リンカーを介して、又は介さず結合するリガンド結合核酸複合体。
[2] PTH1リガンドが、下記式で表されるアミノ酸配列からなるペプチドである、[1]のリガンド結合核酸複合体:
[化1]
A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34
[式中、アミノ酸配列はN末端からC末端に向かって記述したものである。
式中、
A1はAla、Ser、Dapまたは欠損しており;
A2はValまたは欠損しており;
A3はSer,Thr、Aibまたは欠損しており;
A4はGluまたは欠損しており;
A5はLeu、His、Nle、Ile、Cha、β-Nal、Trp、Pal、Acc、Phe
p-X-Pheまたは欠損しており、この際、XはOH、ハロゲン、またはCH3であり;
A6はGln;
A7はLeu、Nle、Ile、Cha、β-Nal、Trp、Pal、Acc、Phep-X-Pheまたは欠損しており、この際、XはOH、ハロゲン、またはCH3であり;
A8はMet、Nva、Leu、Val、Ile、Cha、Acc、Nleまたは欠損しており;
A9はHisまたは欠損しており;
A10はAspまたはAsnであり;
A11はLeu、Lys、Nle、Ile、Cha、β-Nal、Trp、Pal、Acc、Phe
またはp-X-Pheであり、この際、XはOH、ハロゲン、またはCH3であり;
A12はGly、Acc、またはAibであり;
A13はLys;
A14はSerまたはHisであり;
A15はLeu、Nle、Ile、Cha、β-Nal、Trp、Pal、Acc、Phe
またはP-X-Pheであり、この際、XはOH、ハロゲン、またはCH3であり;
A16はSer、Gln、Asn、Ala、またはAibであり;
A17はSer、Asp、Thr、またはAibであり;
A18はMet、Nva、Leu、Val、Ile、Nle、Acc、Cha、またはAibであり;
A19はArg、GluまたはAibであり;
A20はArg;
A21はArg、Val、Acc、Cha、またはMetであり;
A22はPhe、Glu、Aib、Acc、またはChaであり;
A23はPhe、Trp、Leu、Lys、Acc、またはChaであり;
A24はLeu、Lys、Acc、またはChaであり;
A25はHis、Arg、Lys、Aib、Acc、またはGluであり;
A26はHis、Aib、Acc、またはLysであり;
A27はLys、Aib、Leu、hArg、Gln、Acc、またはChaであり;
A28はIle、Leu、Lys、Acc、またはChaであり;
A29はAla、Glu、Acc、またはAibであり;
A30はGlu、Asp、Leu、Nle、Cha、Aib、Acc、またはLysであり;
A31はIle、Val、Leu、Nle、Cha、Lys若しくはAccであり;
A32はHisであり;
A33はThr、Asn、LysまたはCysであり;
A34はPhe、Ala、Tyr、AmpまたはAibである]。
[3] PTH1リガンドが、配列番号1~配列番号168からなる群から選択されるいずれか一つの配列からなるペプチドである、[1]のリガンド結合核酸複合体。
[4] PTH1リガンドが、配列番号1~配列番号164からなる群から選択されるいずれか一つの配列からなるペプチドである、[2]のリガンド結合核酸複合体。
[5] 核酸分子と、PTH1リガンドが、リンカーを介して結合している、[4]のリガンド結合核酸複合体。
[6] リンカーが、切断可能な構造を有する切断性リンカーである、[5]のリガンド結合核酸複合体。
[7] リンカーが、以下の構造を有するリンカーのいずれかである、[5]のリガンド結合核酸複合体。
[9] 核酸分子がADO、ASO、HDO、RNAiから選択される核酸分子である、[1]のリガンド結合核酸複合体。
[10] 核酸分子のアンチセンス鎖が連続する12~30のヌクレオチドからなる、[9]のリガンド結合核酸複合体。
[11] 核酸分子が標的転写因子に対して相補的である核酸配列を有し8~30のヌクレオチドからなるデコイである、[8]のリガンド結合核酸複合体。
[12] 前記オリゴヌクレオチドが、RNAからなるアンチセンス鎖と、前記アンチセンス鎖に相補的である核酸鎖からなるsiRNAである、[9]のリガンド結合核酸複合体。
[13] 核酸分子の核酸鎖は、ヌクレオチド、修飾ヌクレオチド及び/又はヌクレオチドアナログを含む、[9]のリガンド結合核酸複合体。
[14] 核酸分子のアンチセンス鎖のヌクレオチド、修飾ヌクレオチド及びヌクレオチドアナログの総数が、12~30ヌクレオチドからなる、[13]のリガンド結合核酸複合体。
[15] 核酸分子がHDOであり、HDOのアンチセンス鎖及び相補鎖のヌクレオチド、修飾ヌクレオチド及びヌクレオチドアナログの総数が、それぞれ12~30ヌクレオチドからなる、[13]のリガンド結合核酸複合体。
[16] アンチセンス鎖は、ギャップマーであり、ヌクレオチド及び/又は修飾ヌクレオチドを含むギャップ領域と、その5’末側及び/又は3’末側に配置される1又は複数のヌクレオチドアナログ及び/又は修飾ヌクレオチドを含むウィング領域を含む、[15]のリガンド結合核酸複合体。
[17] アンチセンス鎖は、非ギャップマーであり、ヌクレオチド、修飾ヌクレオチド及び/又はヌクレオチドアナログを含む、[15]のリガンド結合核酸複合体。
[18] 相補鎖は、ヌクレオチド、修飾ヌクレオチド及び/又はヌクレオチドアナログを含む、[17]のリガンド結合核酸複合体。
[19] 相補鎖は、ヌクレオチド及び/又は修飾ヌクレオチドを含むセンター領域と、その5’末側及び/又は3’末側に配置される1又は複数のヌクレオチドアナログ及び/又は修飾ヌクレオチドを含むウィング領域を含む、[16]のリガンド結合核酸複合体。
[20] 修飾ヌクレオチドは、2’-O-CH3基又は2’-O-CH2CH2OCH3(MOE)基を含むヌクレオチドである、[13]のリガンド結合核酸複合体。
[21] ヌクレオチドアナログは、LNA、cEt-BNA、アミドBNA(AmNA)及びcMOE-BNAからなる群から独立して選択される架橋化ヌクレオチドを含む、[13]のリガンド結合核酸複合体。
[22] ヌクレオチドアナログは、PNA、GNA、TNA、cEt、tcDNA、モルホリノ核酸及びBNA、Guanidine bridged nucleic acid (GuNA)及び2’-O,4’-C-Spirocyclopropylene bridged nucleic acid(scpBNA)からなる群から独立して選択される、[13]に記載のリガンド結合核酸複合体。
[23] 核酸分子における少なくとも1つのヌクレオチド若しくは修飾ヌクレオチドがホスホロチオエート化若しくはボラノホスフェート化されている、[13]のリガンド結合核酸複合体。
[24]PTH1受容体を発現する被験体の臓器において標的転写産物の発現量を減少させるためのアンチセンス鎖と、該アンチセンス鎖を被験体の臓器にデリバリーするためのPTH1リガンドを有するリガンド結合核酸複合体であって、該アンチセンス鎖は、標的転写産物の少なくとも一部にハイブリダイズすることが可能な塩基配列を含み、かつ、標的転写産物に対してアンチセンス効果を有する、リガンド結合核酸複合体。
[25]核酸複合体が第1核酸鎖と第2核酸鎖とからなる二本鎖核酸剤であり、該第1核酸鎖は、標的転写産物の少なくとも一部にハイブリダイズすることが可能な塩基配列を含み、かつ、標的転写産物に対してアンチセンス効果を有し、該第2核酸鎖は、該第1核酸鎖に相補的な塩基配列を含み、かつ、PTH1リガンドと結合しており、該第1核酸鎖は、該第2核酸鎖にアニールしている、[24]のリガンド結合核酸複合体。
[26]静脈内投与用のリガンド結合核酸複合体である、[25]のリガンド結合核酸複合体。
本明細書は本願の優先権の基礎となる日本国特許出願番号2021-179771号の開示内容を包含する。
本発明において「核酸複合体」とは、標的遺伝子、その転写産物又はその翻訳産物の発現又は編集を調節する核酸分子のことである。当該核酸分子の例としては、標的遺伝子又はその転写産物に相補的な核酸配列を有しアンチセンス活性を有する核酸分子が挙げられる。当該核酸分子は、より具体的には、一本鎖アンチセンス鎖(single stranded Antisense Oligonucleotide,ASO)、miRNA,anti-miR,RNA干渉(RNAi)、short interference RNA(siRNA)、short hairpin RNA(shRNA)、アンチセンス二本鎖核酸(antisense double-stranded DNA oligonucleotide,ADO)、ヘテロ二本鎖核酸(Hetero-duplex oligonucleotide,HDO)が挙げられる。
「リガンド」とは、生体分子に結合して複合体を形成して生物学的な目的を果たす物質を意味する。ある場合、リガンドは標的への送達機能を有する。例えば、肝臓等に特異性高く効率的にある核酸複合体を送達できるという観点から、好ましいリガンドとして脂質が挙げられる。このような脂質としては、コレステロール、脂肪酸等の脂質(例えば、ビタミンE(トコフェロール類、トコトリエノール類)、ビタミンA,ビタミンD)、ビタミンK等の脂溶性ビタミン(例えば、アシルカルニチン)、アシルCoA等の中間代謝物、糖脂質、グリセリド、並びにそれらの誘導体等を例示することができるが、これらの中では、より安全性が高いという観点から、好ましいリガンドとしてコレステロール、ビタミンE(トコフェロール類、トコトリエノール類)が挙げられる。また、脳に特異性高く効率的に核酸分子を送達できるという観点から、好ましいリガンドとして糖(例えば、グルコース、スクロース)が挙げられる。また、各臓器の細胞表面にある各種タンパク質に結合することにより、当該臓器に特異性高く効率的に核酸複合体を送達できるという観点から、好ましいリガンドとして受容体のリガンドや抗体、及び/又はそれらの断片等のペプチド又はタンパク質が挙げられる。
[化2]
A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34
[式中、アミノ酸配列はN末端からC末端に向かって記述したものである。
式中、
A1はAla、Ser、Dapまたは欠損しており;
A2はValまたは欠損しており;
A3はSer,Thr、Aibまたは欠損しており;
A4はGluまたは欠損しており;
A5はLeu、His、Nle、Ile、Cha、β-Nal、Trp、Pal、Acc、Phe
p-X-Pheまたは欠損しており、この際、XはOH、ハロゲン、またはCH3であり;
A6はGln;
A7はLeu、Nle、Ile、Cha、β-Nal、Trp、Pal、Acc、Phep-X-Pheまたは欠損しており、この際、XはOH、ハロゲン、またはCH3であり;
A8はMet、Nva、Leu、Val、Ile、Cha、Acc、Nleまたは欠損しており;
A9はHisまたは欠損しており;
A10はAspまたはAsnであり;
A11はLeu、Lys、Nle、Ile、Cha、β-Nal、Trp、Pal、Acc、Phe
またはp-X-Pheであり、この際、XはOH、ハロゲン、またはCH3であり;
A12はGly、Acc、またはAibであり;
A13はLys;
A14はSerまたはHisであり;
A15はLeu、Nle、Ile、Cha、β-Nal、Trp、Pal、Acc、Phe
またはP-X-Pheであり、この際、XはOH、ハロゲン、またはCH3であり;
A16はSer、Gln、Asn、Ala、またはAibであり;
A17はSer、Asp、Thr、またはAibであり;
A18はMet、Nva、Leu、Val、Ile、Nle、Acc、Cha、またはAibであり;
A19はArg、GluまたはAibであり;
A20はArg;
A21はArg、Val、Acc、Cha、またはMetであり;
A22はPhe、Glu、Aib、Acc、またはChaであり;
A23はPhe、Trp、Leu、Lys、Acc、またはChaであり;
A24はLeu、Lys、Acc、またはChaであり;
A25はHis、Arg、Lys、Aib、Acc、またはGluであり;
A26はHis、Aib、Acc、またはLysであり;
A27はLys、Aib、Leu、hArg、Gln、Acc、またはChaであり;
A28はIle、Leu、Lys、Acc、またはChaであり;
A29はAla、Glu、Acc、またはAibであり;
A30はGlu、Asp、Leu、Nle、Cha、Aib、Acc、またはLysであり;
A31はIle、Val、Leu、Nle、Cha、Lys若しくはAccであり;
A32はHisであり;
A33はThr、Asn、LysまたはCysであり;
A34はPhe、Ala、Tyr、AmpまたはAibである]。
GlyまたはG :グリシン
AlaまたはA :アラニン
ValまたはV :バリン
LeuまたはL :ロイシン
IleまたはI :イソロイシン
SerまたはS :セリン
ThrまたはT :スレオニン
CysまたはC :システイン
MetまたはM :メチオニン
GluまたはE :グルタミン酸
AspまたはD :アスパラギン酸
LysまたはK :リジン
ArgまたはR :アルギニン
HisまたはH :ヒスチジン
PheまたはF :フェニールアラニン
TyrまたはY :チロシン
TrpまたはW :トリプトファン
ProまたはP :プロリン
AsnまたはN :アスパラギン
GlnまたはQ :グルタミン
Aib :アミノイソブチル酸
Nle :ノルロイシン
β-Ala:β-アラニン
hPTH:ヒトPTH
Boc :t-ブトキシカルボニル
Fmoc:9-フルオレニルメトキシカルボニル
Nva :ノルバリン
Abu :α-アミノブチリル酸
Ahc :1-アミノシクロヘキシルカルボン酸
hArg:ホモアルギニン
Cha:2-アミノ-3-シクロヘキシルプロピオン酸
Npa:3-(2-ナフチル)-アラニン
Dap:2,3-アミノプロピオン酸
D-Ser:(D)-Ser
D-Leu:(D)-Leu
D-Trp:(D)-Trp
リガンドと核酸の結合の仕方としては、リガンドの結合可能な基と核酸分子の結合可能な基を共有結合、非共有結合、例えば水素結合、静電相互作用、疎水性相互作用等により結合することができる。リガンドの結合可能な基とは例えば、PTH1リガンドであるペプチドが有するアミノ基、ヒドロキシ基、カルボン酸、チオール基、ジスルフィド、アジド基等があげられるが、これに限定されるものではない。核酸の結合可能な基としては、ヌクレオシドの糖の2位の炭素、3位のヒドロキシ基または5位のヒドロキシ基、ヌクレオチドの5位のリン酸基、またはヌクレオシドの塩基部分が挙げられる。また、核酸分子の結合可能な基としては、オリゴヌクレオチド中のリン酸基も挙げられる。
核酸分子とリガンドは、リンカーを介して、又は介さず結合させる。
ある実施態様では、リガンドは、リンカーを介して核酸分子に結合される。核酸分子がHDOの場合、リガンドはHDOのアンチセンス鎖及び/又は相補鎖にリンカーを介して結合されていてもよい。リンカーは、切断性(cleavable)又は非切断性(uncleavable)リンカーを用いることが可能である。
上の化6の式で示すリンカーを得ることができる。
化8の式で示す化合物を、固相担体上のオリゴヌクレオチド部位Yと反応させて、固相担体から開裂することで
上の化9の式で示すリンカーを得ることができる。
と、末端アミンを有するオリゴヌクレオチドと反応させて、
上の化15の式で表すリンカーを得た。
を、末端アミンを有するオリゴヌクレオチドと反応させて、
上の化20の式で示すリンカーを得た。
を、末端アミンを有するオリゴヌクレオチドと反応させて、
上の化24の式で示すリンカーを得た。
特定の実施形態において、リンカーはジスルフィド結合を含むリンカーを使用することができる。特定の実施形態において、リンカーは、リガンド結合部分とジスルフィド結合を形成する活性化ジスルフィドを含む。
とを、末端アミンを有するオリゴヌクレオチドと反応させて、
上の化29の式で示すリンカーを得た。
上の化31の式で示すリガンド結合部分にリンカーを導入したリンカーを得た。
本発明のリガンド結合核酸複合体が標的とする疾患としては、標的とする臓器及び臓器中の組織、細胞が関連する疾患であればよい。例えば、そのような疾患として、糖尿病、メタボリックシンドローム、心臓病、筋ジストロフィー、筋強直性ジストロフィー、ベッカー型筋ジストロフィー、先天性筋ジストロフィー、デュシェンヌ型筋ジストロフィー、遠位型筋ジストロフィー、エメリ・ドレフュス型筋ジストロフィー、顔面肩甲上腕型筋ジストロフィー、肢帯型筋ジストロフィー、眼咽頭型筋ジストロフィー、慢性腎臓病(CKD)、腎線維症、糖尿病性腎症、慢性糸球体腎炎、IgA腎症、ループス腎炎、原発性糸球体疾患、慢性閉塞性肺疾患(COPD)、肺気腫、間質性肺炎、肺線維症、心疾患、筋疾患等が挙げられるが、これらに限定されるものではない。
本発明のPTH1リガンドである表1に記載のポリペプチドは表4に示す合成パターンでオリゴ核酸に導入する。
本発明の核酸複合体は、標的遺伝子又は標的転写産物に対しハイブリダイズ可能なアンチセンス鎖を有しアンチセンス効果を奏するものであればよく、二本鎖の場合はさらにアンチセンス鎖とハイブリダイズ可能な相補鎖の組み合わせを用いることができる。例えば次の配列からなるASO、HDO、siRNAから選択することが可能であるし、異なる疾患を標的とする場合、標的転写産物が異なることから、それぞれの標的に応じた核酸配列を持つアンチセンス鎖を有する核酸分子を用いることができる。
試薬
この実施例で使用する核酸複合体は、実施例2で作製したマウスMalat1 ncRNAをターゲットとする16merのHDOにリガンドとしてL001をコンジュゲートしたL001-HDO6である。発明者らは、これらのオリゴを生理食塩水(大塚製薬)にて100μMに調製し、2本鎖のHDOはブロックバス(CDB-105、アズワン)にて90℃5分間変性させ、その後自然冷却(約2時間)で室温に戻すことでアニーリング操作を行った。
PTH1受容体及びPTH、PTHrPは、ヒトとマウス間で種差が少ないため、被験体としてc57BL/6Jマウス(25匹、日本チャールズリバー、雌性、入荷時4週齢)を用いた。動物は室温(24±2℃)、湿度(55±5%)および12時間照明(8:00-20:00)の環境下でプラスチックの飼育ゲージに5匹ずつ飼育し、自由飲水と固形飼料(MF、オリエンタル酵母工業)を与え、1週間を馴化した。
マウスの体重によりVehicle(Saline、大塚製薬)投与群、L001相補鎖(1μmol/kg)投与群及びL001-HDO6(1μmol/kg)投与群に分けた(各群動物n=5)。試薬投与当日、マウスを覚醒下で保定器にて保定し、尾静脈より試剤をゆっくり投与(10ml/kg、Day 0)した。L001相補鎖(1μmol/kg)投与群は、ネガティブコントロールとして使用した。投与後、投与部位の止血を確認し、飼育ケージに戻した。投与3日後(Day 3)に剖検を実施した。剖検当日、マウスの体重を測定し、イソフルラン(3-5%で導入、1-3%で維持)麻酔下にて心内採血(テルモシリンジSS-01P2525、抗凝固剤ヘパリン含有)を行い、放血により安楽死させた。開腹し、肝臓、腎臓を摘出した。摘出した臓器は速やかにISOGENに浸し、mRNA抽出に供した。血液サンプルは1.5 mlエッペンチューブに入れ、10000rpm/5分遠心し、上清を冷凍(-30℃)保存し、血中肝臓逸脱酵素Alanine aminotransferase(ALT)とAspartate aminotransferase(AST)の測定に用いた。
1 一般状況
マウスの毛並み、行動、糞便など投与前後に明確な変化は観察されなかった。試薬は尾静脈より10ml/kgの用量で投与したが、投与直後に行動異変は観察されなかった。
投与前各群動物の平均体重17gで、投与前後で大きく変化は認められなかった。また、Vehicle群に比べ、オリゴ投与群の平均体重は有意な変化は認められなかった(図1)。
図2AはマウスにmMalat1オリゴを投与3日後、血中ALT活性の変化を示す。 図2BはマウスにmMalat1オリゴを投与3日後、血中AST活性の変化を示す。 mMalat1オリゴ投与群のALTおよびAST活性は、Vehicle投与群に比べ、有意な変化は認められなかった。
4.1 肝臓
肝臓のmMalat1 ncRNA発現は、L001-HDO6投与群はVehicle投与群及びL001相補鎖投与群に比べ有意に低下した(図3)。
腎臓のmMalat1 ncRNA発現は、L001-HDO6投与群はVehicle投与群及びL001相補鎖投与群に比べ有意に低下した(図4)。
L001-HDO6-Alexa488投与後腎臓の免疫染色像による組織学的検査
免疫染色像による組織学的検査に用いる蛍光標識HDOを図5に示す。
1 糸球体
糸球体内からはAlexa-488の蛍光がL001-HDO6試薬投与10分後で薄く観察されるが、6、24及び72時間のいずれの観察時点で観察されなかった。
尿細管細胞ではAlexa-488の蛍光がL001-HDO6試薬投与10分後から観察され、6時間で強くなり、24時間では最も強く、72時間においても多くの尿細管から蛍光が観察された。
この実施例で使用する核酸複合体は、実施例で作製したマウスMalat1 ncRNAをターゲットとする16merのHDO或いはASOにPTH1リガンドを付与したものである。発明者らは、これらのオリゴを生理食塩液(大塚製薬工場)にて調製し、動物評価用のオリゴはブロックバス(CDB-105、アズワン)にて、細胞評価用の2本鎖のHDOはT100 サーマルサイクラー(Bio-Rad)にて、95℃で10分間変性させ、その後、冷却(約2時間)し室温に戻すアニーリング操作を行った。動物評価用のオリゴは生理食塩液で100 nmol/mLに最終調製し、細胞評価用のオリゴは0.1% FCSのDMEM(Invitrogen)にて種々の濃度に調製した。
C57BL/6Jマウス(日本SLC、雌性、入荷時4週齢)を用いた。動物は室温(24±2℃)、湿度(55±5 %)および12時間照明(7:00-19:00)の環境下でプラスチックの飼育ゲージに5匹ずつ飼育し、自由飲水と固形飼料(MF、オリエンタル酵母工業)を与え、1週間を馴化した。
マウスの体重によりVehicle(Saline、大塚製薬工場)投与群及び種々のPTH1リガンド-HDO(1μmol/kg)投与群に分けた(各群動物n=5)。試薬投与当日、マウスを覚醒下で保定器にて保定し、尾静脈或いは頚背部皮下より試剤をゆっくり投与(10mL/kg、Day 0)した。投与後、投与部位の止血を確認し、飼育ケージに戻した。投与3日後(Day 3)に剖検を実施した。剖検当日、イソフルラン(3-5%で導入、1-3%で維持)麻酔下にて放血により安楽死させた。開腹し、肝臓、腎臓、肺、心臓、及び大腿筋を摘出した。摘出した臓器は速やかにISOGENに浸漬し、mRNA抽出に供した。
1. PHT1リガンドのペプチドのアミノ酸配列の長さを変更したリガンドの検討
腎臓のMalat1 ncRNA発現は、PTH1リガンドを付与しないHDO静脈内投与群(HDO)では統計学的有意な抑制を示さなかったが、PTH1リガンドを付与したHDO静脈内投与群(L001-HDO6、L003-HDO6、L005-HDO6及びL010-HDO6)では、いずれもSaline投与群に比べ統計学的有意に低下した。またHDOとの比較においてもPTH1リガンドを付与したHDO静脈内投与群(L001-HDO6、L003-HDO6、L005-HDO6及びL010-HDO6)はいずれも統計学的有意に腎臓のMalat1 ncRNA発現を低下した。結果を図7に示す。
腎臓のMalat1 ncRNA発現は、リガンドを付与しないHDO皮下投与群(HDO)では統計学的有意な抑制を示さなかった。一方、リガンドを付与したHDO皮下投与群(L031-HDO6及びL021-HDO6)では、いずれもSaline投与群に比べ統計学的有意に低下した(図8)。また、L021-HDO6は、皮下投与群も静脈内投与群も同程度に有意に標的遺伝子の阻害活性を示した。
細胞
PiggyBacトランスポゾン法によりNIH/3T3細胞株にmouse Pth1R(mPth1R)を安定発現させた細胞株を用いた。PTH1リガンドの作用評価に用いたmPth1Rの安定発現クローン細胞株は、33Kのアゴニスト活性でIC50がおおよそ100pMのcAMP誘導能を有する細胞株である。
mPth1R安定発現細胞株を96穴プレートに1.5x104個/wellで播種した。播種24時間後に各穴のmediumを吸引除去し、0.1% FBSを含むDMEMで調製された種々の濃度のPTH1リガンド-HDOを100 μLずつ各穴に添加した。細胞からのtotal RNA抽出はSV 96 Total RNA Isolation System(Promega)のRNA精製キットのプロトコールに則り行った。すなわちPTH1リガンド-HDO添加から24時間後に各穴のmediumを吸引除去し、次いでPBSにて各穴の洗浄を行った。PBSを吸引除去し、次いでRNA精製キット付属のRNA Lysis Bufferを各穴に100 μLずつ加え、細胞の溶解を行った。これ以降の操作についてはSV 96 Total RNA Isolation System(Promega)に従いtotal RNAを得た。Total RNAからcDNAへの逆転写はPrimeScriptTM RT Master Mix (TaKaRa)を用いた。各遺伝子のmRNA発現はリアルタイムPCRシステムStep One Plus(Applied Biosystems)にて計測した。標的遺伝子の解析にはMalat1(Mm 01227912-s1、Applied Biosystems)を用い、内部標準遺伝子としてGapdh(Mm99999915_g1、Applied Biosystems)のTaqManプローブを用いた。
L021-HDO6、L003-HDO6、L005-HDO6、L010-HDO6は、いずれも濃度依存的にMalat1 ncRNA発現を低下させ、それぞれのIC50は、46.8nM、88.9nM、121.3nM及び166.7nMであった(図9)。配列番号21、配列番号3、配列番号5、配列番号6、配列番号10のペプチドからなるPTH1リガンドを結合したHDOは、標的遺伝子に対し濃度依存的なアンチセンス効果を有することを示す結果となった。
L021-HDO6及びL011-HDO6は、いずれも濃度依存的にMalat1 ncRNA発現を低下させ、それぞれのIC50は、6.94-10.2nM及び11.8-14.1nMであった(図10)。配列番号21、配列番号11のペプチドからなるPTH1リガンドを結合したHDOは、標的遺伝子に対し濃度依存的なアンチセンス効果を有することを示す結果となった。
L031-HDO6及びL040-HDO6は、いずれも濃度依存的にMalat1 ncRNA発現を低下させ、それぞれのIC50は、41.5-71 nM及び92.2-111nMであった(図11)。配列番号31、配列番号40のペプチドからなるPTH1リガンドを結合したHDOは、標的遺伝子に対し濃度依存的なアンチセンス効果を有することを示す結果となった。
L089-HDO6及びL098-HDO6は、いずれも濃度依存的にMalat1 ncRNA発現を低下させ、それぞれのIC50は、1.14-1.61nM及び47.7-82.7nMであった(図12)。配列番号89、配列番号98のペプチドからなるPTH1リガンドを結合したHDOは、標的遺伝子に対し濃度依存的なアンチセンス効果を有することを示す結果となった。
L165-HDO6及びL168-HDO6は、いずれも濃度依存的にMalat1 ncRNA発現を低下させ、それぞれのIC50は、27.8-185 nM及び11.4-96.5nMであった(図13)。配列番号165、配列番号168のペプチドからなるPTH1リガンドを結合したHDOは、標的遺伝子に対し濃度依存的なアンチセンス効果を有することを示す結果となった。
PTH1リガンドL001を結合したASOであるL001-ASOは、いずれも濃度依存的にMalat1 ncRNA発現を低下させ、IC50は1.25 nMであった(図14)。配列番号1のペプチドからなるPTH1リガンドを結合したASOは、標的遺伝子に対し濃度依存的なアンチセンス効果を有することを示す結果となった。本発明のPTH1リガンドは一本鎖核酸分子に結合して、標的遺伝子に対し濃度依存的なアンチセンス効果を示した。
本発明の核酸複合体は、標的遺伝子又は標的転写産物に対しハイブリダイズ可能なアンチセンス鎖を有しアンチセンス効果を奏するものであればよく、二本鎖の場合はさらにアンチセンス鎖とハイブリダイズ可能な相補鎖の組み合わせを用いることができる。例えば次の配列からなるsiRNAから選択することが可能であるし、異なる疾患を標的とする場合、標的転写産物が異なることから、それぞれの標的に応じた核酸配列を持つアンチセンス鎖を有する核酸分子を用いることができる。
配列番号182は配列番号181のアンチセンス鎖に相補的な配列を有する23個の核酸(21mer)からなる相補鎖であり、配列番号181のアンチセンス鎖にハイブリダイズ可能な配列で構成されている。
PiggyBacトランスポゾン法によりNIH/3T3細胞株にmouse Pth1R (mPth1R)を安定発現させた細胞株を用いた。
mPth1R安定発現細胞株を96穴プレートに3.75x103個/wellで播種した。播種4時間後に各穴のmediumを吸引除去し、Opti-MEMで調製された種々の濃度のL010-siRNAを100μLずつ各穴に添加した。細胞からのtotal RNA抽出はSV96 Total RNA Isolation System(Promega)のRNA精製キットのプロトコールに則り行った。すなわちL010-siRNA添加から72時間後に各穴のmediumを吸引除去し、次いでPBSにて各穴の洗浄を行った。PBSを吸引除去し、次いでRNA精製キット付属のRNA Lysis Bufferを各穴に100 μLずつ加え、細胞の溶解を行った。これ以降の操作についてはSV96 Total RNA Isolation Systemに従いtotal RNAを得た。Total RNAからcDNAへの逆転写はPrimeScript RT Mster Mix(TaKaRa)を用いた。各遺伝子のmRNA発現はリアルタイムPCRシステムStep One Plus(Applied Biosystems)にて計測した。標的遺伝子の解析にはGapdh(Mm99999915_g1、Applied Biosystems)を用い、内部標準遺伝子としてActb(Mm01205647_g1、Applied Biosystems)のTaqManプローブを用いた。すべての測定値はN=4の平均値±標準偏差で表した。
Claims (26)
- 標的遺伝子、その転写産物又はその翻訳産物の発現又は編集を調節する核酸分子と、PTH1リガンドが、リンカーを介して、又は介さず結合するリガンド結合核酸複合体。
- PTH1リガンドが、下記式で表されるアミノ酸配列からなるペプチドである、請求項1に記載のリガンド結合核酸複合体:
[化1]
A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34
[式中、アミノ酸配列はN末端からC末端に向かって記述したものである。
式中、
A1はAla、Ser、Dapまたは欠損しており;
A2はValまたは欠損しており;
A3はSer,Thr、Aibまたは欠損しており;
A4はGluまたは欠損しており;
A5はLeu、His、Nle、Ile、Cha、β-Nal、Trp、Pal、Acc、Phe
p-X-Pheまたは欠損しており、この際、XはOH、ハロゲン、またはCH3であり;
A6はGln;
A7はLeu、Nle、Ile、Cha、β-Nal、Trp、Pal、Acc、Phep-X-Pheまたは欠損しており、この際、XはOH、ハロゲン、またはCH3であり;
A8はMet、Nva、Leu、Val、Ile、Cha、Acc、Nleまたは欠損しており;
A9はHisまたは欠損しており;
A10はAspまたはAsnであり;
A11はLeu、Lys、Nle、Ile、Cha、β-Nal、Trp、Pal、Acc、Phe
またはp-X-Pheであり、この際、XはOH、ハロゲン、またはCH3であり;
A12はGly、Acc、またはAibであり;
A13はLys;
A14はSerまたはHisであり;
A15はLeu、Nle、Ile、Cha、β-Nal、Trp、Pal、Acc、Phe
またはP-X-Pheであり、この際、XはOH、ハロゲン、またはCH3であり;
A16はSer、Gln、Asn、Ala、またはAibであり;
A17はSer、Asp、Thr、またはAibであり;
A18はMet、Nva、Leu、Val、Ile、Nle、Acc、Cha、またはAibであり;
A19はArg、GluまたはAibであり;
A20はArg;
A21はArg、Val、Acc、Cha、またはMetであり;
A22はPhe、Glu、Aib、Acc、またはChaであり;
A23はPhe、Trp、Leu、Lys、Acc、またはChaであり;
A24はLeu、Lys、Acc、またはChaであり;
A25はHis、Arg、Lys、Aib、Acc、またはGluであり;
A26はHis、Aib、Acc、またはLysであり;
A27はLys、Aib、Leu、hArg、Gln、Acc、またはChaであり;
A28はIle、Leu、Lys、Acc、またはChaであり;
A29はAla、Glu、Acc、またはAibであり;
A30はGlu、Asp、Leu、Nle、Cha、Aib、Acc、またはLysであり;
A31はIle、Val、Leu、Nle、Cha、Lys若しくはAccであり;
A32はHisであり;
A33はThr、Asn、LysまたはCysであり;
A34はPhe、Ala、Tyr、AmpまたはAibである]。 - PTH1リガンドが、配列番号1~配列番号168からなる群から選択されるいずれか一つの配列からなるペプチドである、請求項1に記載のリガンド結合核酸複合体。
- PTH1リガンドが、配列番号1~配列番号164からなる群から選択されるいずれか一つの配列からなるペプチドである、請求項2に記載のリガンド結合核酸複合体。
- 核酸分子と、PTH1リガンドが、リンカーを介して結合している、請求項4に記載のリガンド結合核酸複合体。
- リンカーが、切断可能な構造を有する切断性リンカーである、請求項5に記載のリガンド結合核酸複合体。
- 核酸分子が、標的遺伝子又はその転写産物に対して相補的である核酸塩基配列を有するオリゴヌクレオチドからなるアンチセンス鎖を含む核酸分子、標的タンパク質に対して特異的に結合する核酸塩基配列を有するアプタマー及び標的転写因子に対して相補的である核酸配列を有するオリゴヌクレオチドからなるデコイからなる群から選択される核酸分子である、請求項1に記載のリガンド結合核酸複合体。
- 核酸分子がADO、ASO、HDO及びRNAiからなる群から選択される核酸分子である、請求項1に記載のリガンド結合核酸複合体。
- 核酸分子のアンチセンス鎖が連続する12~30のヌクレオチドからなる、請求項9に記載のリガンド結合核酸複合体。
- 核酸分子が標的転写因子に対して相補的である核酸配列を有し8~30のヌクレオチドからなるデコイである、請求項8に記載のリガンド結合核酸複合体。
- 前記オリゴヌクレオチドが、RNAからなるアンチセンス鎖と、前記アンチセンス鎖に相補的である核酸鎖からなるsiRNAである、請求項9に記載のリガンド結合核酸複合体。
- 核酸分子の核酸鎖は、ヌクレオチド、修飾ヌクレオチド及び/又はヌクレオチドアナログを含む、請求項9に記載のリガンド結合核酸複合体。
- 核酸分子のアンチセンス鎖のヌクレオチド、修飾ヌクレオチド及びヌクレオチドアナログの総数が、12~30ヌクレオチドからなる、請求項13に記載のリガンド結合核酸複合体。
- 核酸分子がHDOであり、HDOのアンチセンス鎖及び相補鎖のヌクレオチド、修飾ヌクレオチド及びヌクレオチドアナログの総数が、それぞれ12~30ヌクレオチドからなる、請求項13に記載のリガンド結合核酸複合体。
- アンチセンス鎖は、ギャップマーであり、ヌクレオチド及び/又は修飾ヌクレオチドを含むギャップ領域と、その5’末側及び/又は3’末側に配置される1又は複数のヌクレオチドアナログ及び/又は修飾ヌクレオチドを含むウィング領域を含む、請求項15に記載のリガンド結合核酸複合体。
- アンチセンス鎖は、非ギャップマーであり、ヌクレオチド、修飾ヌクレオチド及び/又はヌクレオチドアナログを含む、請求項15に記載のリガンド結合核酸複合体。
- 相補鎖は、ヌクレオチド、修飾ヌクレオチド及び/又はヌクレオチドアナログを含む、請求項17に記載のリガンド結合核酸複合体。
- 相補鎖は、ヌクレオチド及び/又は修飾ヌクレオチドを含むセンター領域と、その5’末側及び/又は3’末側に配置される1又は複数のヌクレオチドアナログ及び/又は修飾ヌクレオチドを含むウィング領域を含む、請求項16に記載のリガンド結合核酸複合体。
- 修飾ヌクレオチドは、2’-O-CH3基又は2’-O-CH2CH2OCH3(MOE)基を含むヌクレオチドである、請求項13に記載のリガンド結合核酸複合体。
- ヌクレオチドアナログは、LNA、cEt-BNA、アミドBNA(AmNA)及びcMOE-BNAからなる群から独立して選択される架橋化ヌクレオチドを含む、請求項13に記載のリガンド結合核酸複合体。
- ヌクレオチドアナログは、PNA、GNA、TNA、cEt、tcDNA、モルホリノ核酸、BNA、GuNA及びscpBNAからなる群から独立して選択される、請求項13に記載のリガンド結合核酸複合体。
- 核酸分子における少なくとも1つのヌクレオチド若しくは修飾ヌクレオチドがホスホロチオエート化若しくはボラノホスフェート化されている、請求項13に記載のリガンド結合核酸複合体。
- PTH1受容体を発現する被験体の臓器において標的転写産物の発現量を減少させるためのアンチセンス鎖と、該アンチセンス鎖を被験体の臓器にデリバリーするためのPTH1リガンドを有するリガンド結合核酸複合体であって、該アンチセンス鎖は、標的転写産物の少なくとも一部にハイブリダイズすることが可能な塩基配列を含み、かつ、標的転写産物に対してアンチセンス効果を有する、リガンド結合核酸複合体。
- 核酸複合体が第1核酸鎖と第2核酸鎖とからなる二本鎖核酸剤であり、該第1核酸鎖は、標的転写産物の少なくとも一部にハイブリダイズすることが可能な塩基配列を含み、かつ、標的転写産物に対してアンチセンス効果を有し、該第2核酸鎖は、該第1核酸鎖に相補的な塩基配列を含み、かつ、PTH1リガンドと結合しており、該第1核酸鎖は、該第2核酸鎖にアニールしている、請求項24に記載のリガンド結合核酸複合体。
- 静脈内投与用のリガンド結合核酸複合体である、請求項25に記載のリガンド結合核酸複合体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023558051A JPWO2023080159A1 (ja) | 2021-11-02 | 2022-11-02 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021179771 | 2021-11-02 | ||
JP2021-179771 | 2021-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023080159A1 true WO2023080159A1 (ja) | 2023-05-11 |
Family
ID=86241157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/040996 WO2023080159A1 (ja) | 2021-11-02 | 2022-11-02 | リガンド結合核酸複合体 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2023080159A1 (ja) |
WO (1) | WO2023080159A1 (ja) |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6228799B2 (ja) | 1979-02-22 | 1987-06-23 | Toyo Jozo Kk | |
JPH10195098A (ja) | 1996-11-18 | 1998-07-28 | Takeshi Imanishi | 新規ヌクレオチド類縁体 |
JP2002521310A (ja) | 1997-09-12 | 2002-07-16 | エクシコン エ/エス | オリゴヌクレオチド類似体 |
WO2005021570A1 (ja) | 2003-08-28 | 2005-03-10 | Gene Design, Inc. | N−0結合性架橋構造型新規人工核酸 |
WO2007143315A2 (en) | 2006-05-05 | 2007-12-13 | Isis Pharmaceutical, Inc. | Compounds and methods for modulating expression of pcsk9 |
WO2008029619A1 (fr) | 2006-09-07 | 2008-03-13 | Daiichi Sankyo Company, Limited | Oligonucléotide antisens ena ayant une action spécifique de la séquence |
WO2008043753A2 (en) | 2006-10-09 | 2008-04-17 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of pcsk9 |
WO2008049085A1 (en) | 2006-10-18 | 2008-04-24 | Isis Pharmaceuticals, Inc. | Antisense compounds |
JP2008521428A (ja) * | 2004-12-01 | 2008-06-26 | ヘルス プロテクション エージェンシー | 非細胞傷害性プロテアーゼ、ターゲティング部分、プロテアーゼ切断部位およびトランスロケーションドメインを含む融合タンパク質 |
US8299039B2 (en) | 2003-02-28 | 2012-10-30 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
JP2012528596A (ja) * | 2009-06-03 | 2012-11-15 | ダイセルナ ファーマシューティカルズ, インコーポレイテッド | ペプチドダイサー基質剤およびその特異的な遺伝子発現阻害のための方法 |
WO2013089283A1 (en) | 2011-12-16 | 2013-06-20 | National University Corporation Tokyo Medical And Dental University | Chimeric double-stranded nucleic acid |
WO2017131124A1 (ja) | 2016-01-26 | 2017-08-03 | 日産化学工業株式会社 | 一本鎖オリゴヌクレオチド |
WO2018003739A1 (ja) | 2016-06-30 | 2018-01-04 | レナセラピューティクス株式会社 | 機能的リガンドを含む核酸複合体 |
WO2018051762A1 (ja) * | 2016-09-14 | 2018-03-22 | レナセラピューティクス株式会社 | 副作用を減じたアンチセンス核酸 |
JP2020506701A (ja) * | 2017-01-26 | 2020-03-05 | スロゼン, インコーポレイテッド | 組織特異的Wntシグナル増強分子およびその使用 |
JP2021179771A (ja) | 2020-05-13 | 2021-11-18 | Sansan株式会社 | 名刺情報処理装置、名刺情報処理方法、およびプログラム |
-
2022
- 2022-11-02 JP JP2023558051A patent/JPWO2023080159A1/ja active Pending
- 2022-11-02 WO PCT/JP2022/040996 patent/WO2023080159A1/ja active Application Filing
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6228799B2 (ja) | 1979-02-22 | 1987-06-23 | Toyo Jozo Kk | |
JPH10195098A (ja) | 1996-11-18 | 1998-07-28 | Takeshi Imanishi | 新規ヌクレオチド類縁体 |
JP2002521310A (ja) | 1997-09-12 | 2002-07-16 | エクシコン エ/エス | オリゴヌクレオチド類似体 |
US8299039B2 (en) | 2003-02-28 | 2012-10-30 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
WO2005021570A1 (ja) | 2003-08-28 | 2005-03-10 | Gene Design, Inc. | N−0結合性架橋構造型新規人工核酸 |
JP2008521428A (ja) * | 2004-12-01 | 2008-06-26 | ヘルス プロテクション エージェンシー | 非細胞傷害性プロテアーゼ、ターゲティング部分、プロテアーゼ切断部位およびトランスロケーションドメインを含む融合タンパク質 |
WO2007143315A2 (en) | 2006-05-05 | 2007-12-13 | Isis Pharmaceutical, Inc. | Compounds and methods for modulating expression of pcsk9 |
WO2008029619A1 (fr) | 2006-09-07 | 2008-03-13 | Daiichi Sankyo Company, Limited | Oligonucléotide antisens ena ayant une action spécifique de la séquence |
WO2008043753A2 (en) | 2006-10-09 | 2008-04-17 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of pcsk9 |
WO2008049085A1 (en) | 2006-10-18 | 2008-04-24 | Isis Pharmaceuticals, Inc. | Antisense compounds |
JP2012528596A (ja) * | 2009-06-03 | 2012-11-15 | ダイセルナ ファーマシューティカルズ, インコーポレイテッド | ペプチドダイサー基質剤およびその特異的な遺伝子発現阻害のための方法 |
WO2013089283A1 (en) | 2011-12-16 | 2013-06-20 | National University Corporation Tokyo Medical And Dental University | Chimeric double-stranded nucleic acid |
WO2017131124A1 (ja) | 2016-01-26 | 2017-08-03 | 日産化学工業株式会社 | 一本鎖オリゴヌクレオチド |
WO2018003739A1 (ja) | 2016-06-30 | 2018-01-04 | レナセラピューティクス株式会社 | 機能的リガンドを含む核酸複合体 |
WO2018051762A1 (ja) * | 2016-09-14 | 2018-03-22 | レナセラピューティクス株式会社 | 副作用を減じたアンチセンス核酸 |
JP2020506701A (ja) * | 2017-01-26 | 2020-03-05 | スロゼン, インコーポレイテッド | 組織特異的Wntシグナル増強分子およびその使用 |
JP2021179771A (ja) | 2020-05-13 | 2021-11-18 | Sansan株式会社 | 名刺情報処理装置、名刺情報処理方法、およびプログラム |
Non-Patent Citations (3)
Title |
---|
"Click Chemistry for Biotechnology and Materials Science", 2009, WILEY |
KIZAWA HIDEKI, SHOICHI IWAMOTO: "Third nucleic acid medicine platform: heteroduplex oligonucleotides technology", PHARMACIA, vol. 54, no. 11, 1 January 2018 (2018-01-01), pages 1076 - 1078, XP093063171 * |
MOL. THER. NUCLEIC ACIDS, no. 1, 22 January 2013 (2013-01-22) |
Also Published As
Publication number | Publication date |
---|---|
JPWO2023080159A1 (ja) | 2023-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7174384B2 (ja) | キメラ2重鎖核酸 | |
JP6604544B2 (ja) | エクソンスキッピング効果を有する二本鎖アンチセンス核酸 | |
EP2064223B1 (en) | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference | |
JP2012147790A (ja) | エキソンスキッピングを誘発する為の手段及び方法 | |
WO2017068790A1 (ja) | 核酸複合体 | |
JPWO2019022196A1 (ja) | 一本鎖オリゴヌクレオチド | |
EP2389390B1 (en) | Means and methods for modulating notch3 protein expression and/or the coding region of notch3; compositions and use thereof in the treatment of cadasil | |
WO2017068791A1 (ja) | 少なくとも1つのバルジ構造を有する核酸複合体 | |
WO2018220034A1 (en) | Antisense oligonucleotides for modulating htra1 expression | |
CN114901823A (zh) | 诱导外显子50的跳读的反义核酸 | |
US20200123546A1 (en) | Antisense nucleic acid for treating amyotrophy | |
WO2023080159A1 (ja) | リガンド結合核酸複合体 | |
EP3947677A1 (en) | Oligonucleotides for modulating atxn2 expression | |
JP7306653B2 (ja) | 構造強化されたS-TuDを用いた新規がん治療法 | |
KR20160108494A (ko) | β2GPI의 발현을 억제하는 핵산 | |
EP4428238A1 (en) | Ligand-bound nucleic acid complex | |
CN112566922A (zh) | 乙酰辅酶a羧化酶2反义寡核苷酸 | |
WO2024175087A1 (en) | Oligonucleotide targeting sod1 | |
WO2023080225A1 (ja) | 脊髄小脳失調症治療用医薬組成物 | |
KR102397455B1 (ko) | PD-1의 발현을 억제하는 비대칭 siRNA | |
WO2024001172A1 (en) | Oligonucleotide modulators activating complement factor h expression | |
RU2807629C2 (ru) | Антисмысловые олигонуклеотиды ацетил-соа-карбоксилазы-2 | |
RU2807629C9 (ru) | Антисмысловые олигонуклеотиды ацетил-соа-карбоксилазы-2 | |
WO2022255273A1 (ja) | リガンド結合核酸複合体 | |
WO2024091286A1 (en) | Compositions and methods for anti-sense oligonucleotide (aso) treatment of huntington's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22889979 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2023558051 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022889979 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022889979 Country of ref document: EP Effective date: 20240603 |